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1. Introduction 
 
1.0 Virology 
Polyomaviruses are widely distributed in nature and have been described in 
humans, monkeys, cattle, rabbits, mice, hamsters, rats and parakeets. The 
viruses are species specific, infecting one species only or a few closely 
related species. They are classified as polyomaviruses according to the size 
of their virion (diameter 40-45 nm), non-enveloped icosahedral capsid, 
supercoiled, double-strand circular DNA genome, and sequence homology 
with other polyomaviruses. There are three members in the family that infect 
humans; Simian Virus 40 (SV40), BK virus (BKV) and JC virus (JCV). 
SV40, JCV and BKV DNAs contain 5,243, 5,130, and 4,963 base pairs 
respectively (Shah, 1996). BKV, JCV and SV40 share a high degree of 
nucleotide sequence homology. The JCV genome shares 75% homology 
with the BKV genome and 69% with SV40 (Walker and Frisque, 1986). The 
viral genome is functionally divided into 
 (1) An early region, coding for large (T-ag) and small T-antigens (t-ag). 
 (2) A late region, coding for the viral capsid proteins VP1, VP2, VP3, and        
agnoprotein. 
 (3) A noncoding regulatory region (NCCR), containing the origin of 
replication (ori) and transcription control sequences (Fig 1.1). 
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Fig (1.1) BK virus genome, showing Regulatory region, Large T-ag, small 
T-ag and Vp1, Vp2 and Vp3 regions. 
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The early region encodes the viral regulatory proteins, the tumor or T- 
antigens, so called because they can be detected with antisera derived from 
animals bearing tumors induced by these viruses (Dhar et al., 1979). Large 
T-ag is a 708 amino-acid protein which is expressed predominately in the 
cell nucleus. It has multiple functions, including direct initiation of viral 
DNA replication, and regulation of synthesis of both early and late viral 
proteins. Large T-ag is the only viral protein essential for viral DNA 
synthesis.  
Large T-ag interacts with a number of host cell molecules including the 
tumor-suppressor gene retinoblastoma family (Rb) products and p53. 
Initially, the Large T-ag binds to products of the Rb-family (pRb, p107, and 
p130) thereby interfering with their activity and inducing the cell to enter the 
cell cycle (phase S). Subsequently and most importantly, the Large T-ag 
inactivation of p53 allows the re-phosphorylation of pRb through the cyclin-
dependent kinase (cdk) pathway and prevents the p53-mediated cell 
apoptosis of infected cell. This mechanism is used to keep the cells alive 
during productive infection but it may lead to cell transformation (Butel and 
Lednicky, 1999). It is not yet proven that polyomaviruses are etiologic for 
human cancer. However recent investigations have associated them with the 
development of specific cancer types including colorectal cancer, 
glioblastomas, mesotheliomas, prostate cancer and possibly lymphomas 
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(Butel and Lednicky, 1999). VP1, VP2 and VP3 are structural proteins that 
make up the viral capsid. The VP1 gene displays genetic heterogeneity and 
this has lead to the classification of four viral genotypes; I, II, III, IV, type I 
being the most prevalent (Jin et al., 1993). Agnoprotein is synthesized late in 
productive infection and is found in the perinuclear region of the infected 
cell. Although it is not yet known for certain, agnoprotein is thought to play 
a role in several cellular processes, including cell cycle progression, DNA 
repair, viral capsid assembly and virion release from the cell. It is thought 
that it may help with intracellular migration of VP1 to the perinuclear region 
of the infected cell and entry of VP1 into the nucleus, with consequent viral 
assembly and that it could be involved with cell to cell spread of the virus 
(Hou Jong et al., 1987). 
The genomes of JCV, BKV, and SV40 are associated with only a single 
serotype of virus, but extensive variation may occur in the regulatory region 
of each. Because of this, new terminology has appeared to indicate variant 
viral DNA’s which differ primarily in their regulatory regions. Virus strains 
consistently associated with normal populations are termed archetypal 
strains: thought to be involved in transmission of infection. Strains differing 
from the archetypal strain in their regulatory region are termed variant 
strains. These variant or rearranged strains have been postulated to account 
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for their differences in ability to interact with individuals and cause disease 
(Chatterjee et al., 2000). 
 
1.1 Historical Aspects 
Polyomavirus research dates back to the 1950s. Gross et al., 1953, found 
when studying murine leukemia virus (MLV), that passage of virus through 
mice sometimes resulted in salivary gland, or parotid tumors, rather than 
leukemia. In studying this activity he attributed it to a parotid agent which he 
demonstrated to be different to MLV. Stewart et al., 1958 found that on 
inoculation of mice with this agent, the result was the formation of multiple 
tumors and he coined the name polyomavirus, which is derived from the 
Greek poly, meaning many, and the –oma, denoting cancer. SV40 which is a 
member of this family was discovered by Sweet & Hilleman, 1960, who 
were screening polio vaccines produced in monkey cell lines for the 
presence of contaminating viruses. They were able to isolate SV40 from the 
African Green monkey kidney cells used to prepare the vaccines. It became 
clear that a significant number of batches of the poliovirus vaccine were 
contaminated with the virus, and that SV40 was resistant to the formalin 
treatment used to inactivate the poliovirus in the vaccine. Between 1955 and 
1961, millions of Americans were exposed to SV40 as a result of 
immunization with the contaminated poliovirus vaccines. Since this time, 
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SV40 has been demonstrated to be oncogenic when it was inoculated into 
newborn hamsters (Butel and Lednicky, 1999). In these animal models, the 
neoplasm’s induced by SV40 included primary brain cancers, malignant 
mesotheliomas, bone tumors, and systemic lymphomas (Butel and Lednicky, 
1999). There is mounting evidence that SV40 is an emergent human 
pathogen (Martini et al., 2004). Although the prevalence of SV40 infections 
in humans is not known, studies conducted over the last three decades 
indicate that SV40 infections are occurring in child and adult populations 
today. SV40 seroprevalence rates in the general populations of the United 
States and other countries range from 2 to 20% (Butel and Lednicky, 1999). 
During the last decade, many studies have shown the presence of SV40 large 
T-ag DNA or other viral markers in primary human brain and bone cancers, 
malignant mesotheliomas and Non Hodgkin’s lymphoma (Vilchez and 
Butel, 2004). Therefore the major types of human malignancies associated 
with SV40 are the same as those induced by SV40 in animal models. These 
results support the conclusion of the Institute of Medicine of the National 
Academies that “the biological evidence is of moderate strength that SV40 
exposure could lead to cancer in humans under natural conditions” and the 
International Agency for Research on Cancer suggests that SV40 should be 
included in the list of group 2A carcinogens (i.e., agents for which evidence 
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is indicative but not definitive for carcinogenesis in humans) (Vilchez and 
Butel, 2004).  
Two other polyomaviruses of humans have also been described which are 
closely related to SV40. JC virus (JCV) and BK virus (BKV), named from 
the initials of the patients from whom the first isolates were made, which 
were isolated in 1971 from immunocompromised hosts. 
JCV was isolated by Padgett et al., in 1971 by inoculating human fetal brain 
cells with extracts of diseased brain tissue from patients with progressive 
multifocal leukoencephalopathy (PML). That same year Gardner et al., 
1971, isolated BKV from the urine of a Sudanese kidney transplantation 
recipient after inoculation into African green monkey cells. 
Usually primary infections with BKV and JCV occur in childhood (Padgett 
and Walker, 1973), to date it is unclear as to how infection occurs.  The 
viruses persist latently in the infected individual usually in the renal tissue 
(Chesters et al., 1983; Heritage et al., 1981) and only become reactivated in 
times of immune compromise. 
The initial reason for studying these viruses was their oncogenic potential. 
However, these viruses became very useful model systems in molecular 
biology because of the small size of their genomes. In the 1970’s with the 
advent of restriction endonucleases the polyomaviruses became some of the 
first DNA genomes to be completely sequenced (Fiers et al., 1978; Reddy et 
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al., 1978; Soeda et al., 1979 and 1980). For many years polyomaviruses 
were mainly studied for understanding the basic eukaryotic cell processes, 
such as transcription, DNA replication, RNA processing, and oncogenic 
transformation.  
 
1.2 BK virus 
The BKV genome is approximately 5300bp and has early, late, and 
regulatory regions (Reploeg et al., 2001). It has approximately 70% DNA 
sequence homology with SV40. BKV replicates in several human, rodent 
and monkey cell lines but grows slowly in conventional tube cell culture. 
BKV is oncogenic and can transform cells of various animal species in vitro 
including the immortalized human embryonic kidney line (Pater and Pater, 
1986).  
There are many different strains of BKV derived from a variety of sources 
and with unique features. Examples include: Gardner strain (PPPQS) 
derived from urine of a renal allograft patient in 1971 (Gardner et al.,1971); 
DDP strain derived from peripheral blood mononuclear cells (Degener et al., 
1999); NCCR strain which has a rearranged DNA sequence (Moens et al., 
1995); and Dunlop strain (Moens et al., 1999). It is as yet unclear what role 
different strains play in regards to risk of kidney damage such as; BK-
associated nephropathy (BKVN), sensitivity to drug treatment or oncogenic 
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potential. Some authors believe that different BKV genomic variants may 
play a key role in the variable behavior of this viral infection in graft 
recipients (Randhawa et al., 2003).  
JCV is very closely related to BKV. The JCV genome has approximately 
5,130 bp and codes for the same regions as BKV. JCV has 69% sequence 
homology to SV40 and 75% homology to BKV. Sequences showing greatest 
divergence between these three agents lie in the regulatory region. 
 
1.3 Epidemiology 
Polyomaviruses are found throughout the world in birds, rodents, nonhuman 
primates and human populations. SV40 infects only Old World Rhesus 
monkeys, and African and Indian macaques. Most epidemiologic data has 
been collected on BKV and JCV because they are of human origin and cause 
widespread infections globally. Serological studies of populations using 
hemagglutination inhibition assays for the detection of antibodies indicates 
that seroconversion to BKV takes place early in life and conversion to JCV 
occurring later (Fig 1.2). 
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       Fig (1.2). Chart showing antibody levels to the polyomaviruses 
        (BKV, JCV and SV40) in the general population (Vanchiere et al 2005). 
 
 
As shown in Fig 1.2 there is very little information known regarding 
prevalence of antibodies to SV40 in the worldwide population however it is 
known that the prevalence of antibodies to JCV is 10% in children 5 years of 
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age and rises to approximately 65% by adult life (Fig 1.2). Whereas the 
prevalence of antibodies to BKV in healthy adults is predicted to be between 
60-80% and most children will have antibodies by the time they are 10 years 
old (Shah et al., 1973).  
It is thought that primary infection of BKV is typically by the respiratory 
route in children between 2-5 yrs followed by a latent infection in the renal 
tissue, primarily in the renal tubular epithelial cells and bladder epithelium 
(Boldorini et al., 2005). Although it is not known for certain, it is thought 
that primary infection can occur by respiratory tract, oral-enteric, vertical 
transmission from the placental crossing and with organ transplantation. 
Given that BKV remains latent in the kidney, it is no surprise that in kidney 
transplantation the donor kidney itself appears to be an important source of 
infection in transplant recipients. Donor seropositivity has been implicated 
in development of BK viruria, viremia and BKVN in pediatric and adult 
recipients (Bohl et al., 2006).BKVN has emerged as an important cause of 
post-transplant renal allograft loss, affecting ~5% of adult renal transplant 
(RT) recipients.  BKVN is primarily due to the reactivation of BKV in the 
allograft kidney, although the pathogenesis of BKVN is poorly understood.  
While it is clear that BKV can be pathogenic in the setting of severe immune 
compromise, BKV reactivation alone is insufficient to cause BKVN, 
suggesting that host factors play a significant role in pathogenesis.    
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There is conflicting information on risk factors for BKV infection in 
transplant recipients. Risk factors associated with transplantation include, 
cold-ischemia time (the time interval that begins when an organ is cooled 
with a cold perfusion solution after organ procurement surgery and ends 
when the organ is implanted), delayed graft function, immunosuppression, 
treatment of acute rejection with lymphocyte depleting agents or steroids, 
drug-toxicity, and increased number of HLA mismatches. Viral-related 
factors include variants in VP1 and sequence alterations in non-coding 
control region (NCCR). Most of these risk factors are unavoidable, however 
the type and degree of immunosuppression is modifiable and therefore 
efforts have been concentrated here to develop the best treatment for the 
patient.                
         Reactivation of BKV and JCV can also occur during pregnancy, when 
the mother becomes naturally immune-suppressed for the sake of the fetus 
(Coleman et al., 1980; Markowitz et al., 1991). This pregnancy-associated 
immune suppression is primarily driven by the high levels of oestrogen, 
progesterone and cortisol that are circulating in the mother’s blood and 
which are necessary for the maintenance of the pregnancy. 
These hormones suppress the production of Th1 cytokines (TNF-α involved 
in the acute phase reaction and IL-12 involved in the differentiation of naïve 
T cells into Th1 cells) and along with catecholamines, stimulate the 
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production of Th2 cytokines (IL-10 which is an anti-inflammatory cytokine 
which downregulates TNF-α production, IL-8 which is involved in the 
innate immune response and IL-6 involved in the acute phase response). Th1 
cytokines are involved with cellular immunity and proliferation of cytotoxic 
CD8+ T cells which are needed to fight viral infections whereas Th2 
cytokines are involved in humoral immunity which is less effective at 
dealing with a viral infection. 
The resulting effect of these changes is the suppression of cell-mediated 
immunity and the maintenance or stimulation of humoral immunity. The 
immune suppression of pregnancy is a necessary but insufficient explanation 
for the reactivation of persistent viruses, suggesting that individual 
variations in the immune response and immunogenetic makeup contribute to 
the variability in this phenomenon (Coleman et al., 1983). 
        No animal model exists in which human infection can be duplicated 
because neither BKV nor JCV cause productive infection in non-human 
species. Because of this, the natural history of infection with either virus is 
not well understood. Early studies employing Southern hybridization 
detected BKV DNA and/or JCV DNA in a minority of autopsy kidney 
samples. BKV DNA was also found in tonsils and lymphocytes, suggesting 
that the virus might also infect lymphoid tissues. 
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In studies of immunocompromised patients, serological evidence for 
reactivation of BKV has been detected in 22 to 44% of individuals 
undergoing renal transplantation or chemotherapy for malignant disease 
(Shah et al., 1996). Excretion of BKV viral DNA, or virus-infected 
urothelial cells has been repeatedly found in immunosuppressed patients, 
during pregnancy and occasionally in normal children. BKV or JCV 
excretion in the urine of leukemic patients has been found to be 19% (Shah 
et al., 1996) and in the urine of renal transplant patients at 10-60% (Pang et 
al., 2007). BKV is shed in urine of immunocompromised or 
immunosuppressed patients experiencing viral reactivation in levels as high 
as ~1 x 1013 copies per daily output of urine (Leung et al., 2001). In normal 
healthy children and adults studies have shown that urinary excretion of 
BKV occurs intermittently in less than 5% of people (Knowles, 2001). 
 
1.4 Polyomavirus associated diseases 
Several uncommon but serious clinical syndromes have been associated with 
human polyomavirus infections. BKV and JCV are associated with 
persistent infection and diseases of the urogenital tract and the central 
nervous system. Induction of disease is usually linked to states of 
immunoincompetence. The most prominent underlying disorders being 
AIDS and lymphoproliferate disorders. 
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In patients with AIDs, invasion of the central nervous system by JCV causes 
progressive multifocal leukoencephalopathy (PML), an opportunistic 
demyelinating infection which before the advent of AIDS was a very rare 
disease (Holman et al., 1998; Greenlee, 1998; Markowitz et al., 1993). 
Systemic BKV-associated disease in AIDs patients, involves infection of the 
CNS, the lung, the eye, and the kidney (Bratt et al., 1999; Vallbracht et al., 
1993; Smith et al., 1998). Along with multiple lesions in the entire nephron, 
an interstitial tubulonephritis is seen.  
A number of patient groups have been identified that are at an increased risk 
of BKV infection including pregnancy, acquired immune deficiency 
syndrome, uncontrolled diabetes mellitus, and patients on drugs which 
suppress their immune systems which include corticosteroids, cytotoxic 
treatments, anti-metabolites and calcineurin inhibitors. Iatrogenic 
immunosuppression in the course of transplantation or therapy of 
autoimmune disorders can contribute to polyomavirus-induced disease. 
Hemorrhagic cystitis (HC) is a serious BKV-associated complication of 
bone marrow transplantation patients (Apperley et al., 1987; Vogeli et al., 
1999). Prevalence of HC varies from 10% to 68% and leads to severe 
hemorrhage in about 25% of bone marrow recipients (Arthur et al., 1985; 
Azzi et al., 1994; Bedi et al., 1995).  
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In recent studies it has been found that interstitial tubular nephritis is the 
most frequent BKV-associated disease after renal transplant (Mathur et al., 
1997; Pappo et al., 1996; Purighalla et al., 1995). BKVN was first described 
in 1996 in a needle biopsy from a renal transplant recipient suspected of 
having acute rejection. This heralded a new era in the study of BKV. 
Following this finding, many other centers worldwide reported similar 
findings (Hariharan. 2006; Ramos et al., 2002; Randhawa et al 1999; 
Nickeleit et al., 2000). The epidemic of BKVN is thought to be the result of 
administration of potent immunosuppressive drugs such as tacrolimus, 
mycophenolate mofetil and cyclosporine A. (Tacrolimus and cyclosporine A 
are both potent calcineurin inhibitors, calcineurin induces transcription of 
IL-2 which is needed for formation of efffector T cells. Mycophenolate 
mofetil which is also known under its trade name cellcept and myfortic is an 
immunosuppressive anti-rejection drug.) 
Clinical features may mimic graft rejection or drug toxicity but 
histopathologic examination almost always shows interstitial infiltrates of 
plasma cells and lymphocytes. Cells of the transitional bladder epithelium 
were identified as target cells for BKV infection. Virus isolation, DNA 
detection by polymerase chain reaction, electronmicroscopy, 
immunohistologic staining of BKV proteins, and in situ hybridization 
suggests an etiopathologic role of the virus in about 5% of renal transplant 
Polyomavirus Excretion in Pediatric Renal Disease                                          Julie Moran 
____________________________________________________________________________________________________________ 
________________________________________________________________________ 17
patients (Randhawa et al., 1999; Binet et al., 1999).With the introduction of 
new immunosuppressive strategies, the incidence of BKV-associated 
complications in renal transplants increased further (Brennan et al., 2005), 
thus confirming the close relationship between excessive virus growth and 
immunologic impairment. In contrast to renal disease under severe 
immunoincompetence, BKV infection in other patients is most likely in an 
asymptomatic state. Virus DNA is distributed in small foci throughout the 
cortex and medulla of the kidney (Heritage et al., 1981), infecting renal 
epithelial cells and lining cells of ureter and bladder as demonstrated by 
BKV-specific immunostaining (Fig 1.4). 
BKV DNA persists in asymptomatic tissue and exfoliated cells carry 
intranuclear inclusions containing BKV antigen (Shinohara et al., 1993). 
Analysis of BKV and JCV associated diseases disclosed a variety of organs 
and cell types to be susceptible to virus infection; however some essential 
questions still remain to be answered with respect to involvement of distinct 
organs and cell types in polyomavirus persistence. 
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                                   Normal Healthy kidney 
 
Fig 1.3 Histology of a normal healthy kidney (www.tulane.edu) 
 
                             BKV nephropathy of the kidney 
                           
    
Fig 1.4 Image of viral inclusions and cellular changes typical of BK polyoma virus 
nephropathy are seen in the tubular epithelium of this renal transplant case. Jone’s Silver 
Stain, original magnification X1000 (www.standford.edu). 
BKV Viral 
inclusions 
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1.5 Renal Transplants 
Renal transplantation is the treatment of choice for children with end-stage 
renal disease with improved organ and patient survival over the past decade 
(Hariharan et al., 2006). An essential part of the ongoing care of renal 
transplant patients requires immunosuppressant drugs which have 
dramatically reduced the rates of acute allograft rejection over the past 
decade but may have exacerbated the problem of post-transplant infections. 
Donor viral transmission, recipient viral reactivation, and de novo viral 
infection, put the transplant recipient at a high risk of viral induced 
morbidity and mortality because of their immune compromised state. 
BKV reactivation or BKVN in kidney transplant patients accounts for loss of 
allograft in 1-5% of patients. The most striking feature of BK infection in 
kidney transplant recipients is the lack of fever, malaise, leucopenia, anemia 
or other signs and symptoms typical of viral infection, despite viral loads 
exceeding a billion copies/ml in the urine or 100 000 copies/ml in the blood 
(Brennan et al., 2005).  
Post-renal transplant, BKV infection will present itself in a variety of ways: 
asymptomatic viruria with shedding of classic ‘decoy cells’ or virus infected 
uro-epithelial cells in urine (Gardner et al., 1984), tubulo-interstitial 
nephritis and/or BKVN and ureteric obstruction (Vats et al., 2003).  
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The pathogenesis of tissue damage in the infected kidney is a subject of 
considerable interest. Transition from latent to lytic infection is likely 
initiated by ischemia (time without oxygenated blood), calcineurin inhibitor 
or rejection-associated injury. 
The above reasons explain why most cases of BKVN occur in the allograft 
kidney, although disease in the native kidney has been recorded (Randhawa 
et al., 2004; Ginervi et al., 2006).  
DNA microarray analysis of allograft kidney biopsies has shown that BKVN 
is associated with the upregulation of several major groups of mRNAs 
involved in the inflammatory response including; CD8, interferon-γ (IFN- 
γ), CXCR3 and perforin. CD8 is a marker found on cytotoxic T cells; IFN-γ 
has potent anti-viral properties and is the hallmark of the Th1 type T cell 
response. CXCR3 is a chemokine receptor which is expressed on activated 
Th1 cells and promotes their maturation upon ligand interaction and perforin 
is a cytolytic protein found in the granules of CD8+ T cells. The 
upregulation of all these proteins would help the patient to mount an anti-
viral response to the replicating BK virus however it is notable that these 
molecules are also up-regulated in acute cellular rejection, thus illustrating 
why the differential diagnosis between viral nephropathy and acute cellular 
rejection is problematic (Mannon et al., 2005). 
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Since graft rejection usually requires increasing the immunosuppressive 
regimen, whereas BKV viral reactivation is often managed by decreasing 
immunosuppression, determining which of these entities is responsible for 
the pathology is critical. 
The treatment of BKVN is difficult as to date there is no uniformly effective 
anti-viral drug. Prevention of BKVN may be a better strategy than treatment 
of established disease. One large study of patients was conducted using 
prospective monitoring of urine and blood, and preemptive withdrawal of 
immunosuppressive drugs upon development of viremia. This strategy 
resulted in clearance of viremia and viruria and prevention of progression to 
BKVN without increasing the risk of acute rejection (Brennan et al., 2005). 
There is increasing recognition of BKV infection after kidney 
transplantation (Hariharan 2006). However improved techniques of clinical 
monitoring and preemptive interventions will reduce the number of patients 
who develop BKV-induced graft injury. 
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1.6 Detection of Polyomaviruses in Human material 
Laboratory monitoring strategies for BKV are still evolving. Several 
methods have been described for detecting BK and JC virus, including renal 
biopsy, urine cytology, and urine PCR (Arthur et al., 1989; Corey et al., 
1997; Purighalla et al., 1995). PCR is the most sensitive of these assays and 
may also be quantitative (McNees et al., 2005). It is also the only reliable 
method for differentiating JCV and BKV viral genotypes (Boldorini et al., 
2000). JCV excretion in the urine is usually insignificant, although very rare 
cases of JCV-associated nephropathy are on record. 
Polyomavirus urinary tract infection may be suspected if epithelial cells 
containing intranuclear inclusions are detected in the urinary sediment. The 
virus may be specifically diagnosed using immunohistological staining of 
cytological preparations using BKV/JCV specific antibody, enzyme linked 
immunosorbent assay, or PCR. While urinary ‘decoy cells’ have excellent 
sensitivity for the detection of overt BKVN, PCR is four times more 
sensitive than urine cytology for monitoring asymptomatic viruria 
(Randhawa et al., 2004).  
Detectable virus in the blood is more predictive of BKVN than viruria alone. 
It is thought that all patients with active nephropathy will have detectable 
BKV in plasma (viremia). The association of circulating virus with active 
nephropathy has been noted before (Hirsch et al., 2002; Randhawa et al., 
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1999; Vats et al., 2003). The entry of viral DNA into the circulation likely 
occurs at the level of peritubular capillaries, following tubular destruction 
and release of free virus in the interstitial compartment. Detection of BKV in 
blood is highly probable of BKVN however definitive diagnosis of BKVN 
requires a biopsy and demonstration of BKV inclusions in tubular epithelial 
or Bowman’s capsular epithelial cells. Viral infection is accompanied by 
varying degrees of inflammatory cell infiltrates, tubular atrophy and fibrosis. 
Confirmatory immunohistochemistry or in situ hybridization are usually 
preformed using antibodies against specific BKV proteins or probes 
complementary to viral DNA. Viral particles can also be demonstrated by 
electron microscopy. Ideally two biopsy cores should be examined as BKVN 
can be focal in distribution. 
 
1.7 Molecular Methods of Detection  
At present the preferred method for detection of polyomaviruses in the blood 
and urine is by real-time polymerase chain reaction (RT-PCR). RT-PCR 
assays are advantageous over traditional PCR protocols for the detection of 
polyomavirus DNA for several reasons. The sensitivity of detection of RT-
PCR is increased from 10- to 100- fold over conventional PCR protocols 
where the lowest copy number detected by PCR agarose-gel analysis was 
1000 copies (McNees et al., 2005).  
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RT-PCR also called quantitative real time PCR (QRT-PCR) or kinetic PCR 
is a technique used to simultaneously quantify and amplify a specific part of 
a given DNA molecule. It is used to determine whether a specific sequence 
is present and if so the number of copies present in a sample. The procedure 
is similar to conventional PCR, but the DNA is quantified after each round 
of amplification; this is the “real-time” aspect of it. There are two common 
methods of quantification; fluorescent dyes that intercalculate with ds-DNA 
and oligonucleotide probes that fluoresce when hybridized with 
complementary DNA. These fluorescent probes are the most accurate of the 
methods. The probe is commonly tagged with a fluorescent reporter at one 
end and a quencher of fluorescence at the opposite end, this probe is usually 
referred to as a Taq Man probe. The close proximity of the reporter to the 
quencher prevents fluorescence until addition of taq polymerase which has 
exonuclease activity (enzymes that cleave nucleotides) and breaks the 
reporter quencher proximity and thus allows the emission of fluorescence 
(Fig 1.5).  
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                                     Real-time PCR Method 
            
 
 Fig 1.5 Real-time method, when probe hybridizes with target nucleotides 
the quencher is released allowing emission of fluorescence 
(www.takarabiousa.com/images/PCR_TPM.gif). 
 
 
As there is an increase in the product targeted by the reporter probe after 
each PCR cycle there is a proportional increase in fluorescence which is 
recorded by the real-time thermocycler (Fig 1.6).  
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                                           Real-time PCR curve 
 
 
Fig 1.6  Real-time PCR curve. As there is an increase in the product 
targeted by the reporter probe after each PCR cycle there is a proportional 
increase in fluorescence after each cycle (www.viracor.com/images/Sub-
Technology-Pic-PCR.gif). 
 
The probes specific to the sequence of interest in our study, are labeled with 
FAMTM (6-carboxyfluorescein) the reporter, at the 5’ends and with MGB 
(minor groove binder) the quencher, at the 3’ends.  
During the extension phase of the cycle, fluorescence is generated as the 
reporter FAM on the 5’end of the probe is cleaved by the 5’-3’ exonuclease 
activity of the Taq polymerase; reporter dye is released and accumulates as 
the reaction progresses.  
Polyomavirus Excretion in Pediatric Renal Disease                                          Julie Moran 
____________________________________________________________________________________________________________ 
________________________________________________________________________ 27
ROXTM (passive reference dye) is a component of the TaqMan Universal 
PCR master mix and by dividing the intensity of the reporter dye by the 
intensity of ROX; corrections can be made for any volume fluctuations made 
during the preparation of the reaction. The threshold cycle number, CT is the 
cycle number at which significant increase in reporter fluorescence is first 
detected and this threshold is set 10 standard deviations above the mean 
background fluorescence detected in the first 15 cycles. 
When choosing primers and probes it is important to design them to 
mimimize the possibility of crossreactivity. The Large T-ag sequences of the 
BKV, JCV and SV40 viruses share considerable homology so primer and 
probe designs must be chosen to maximize the differences among the 
sequences in this region. In previous studies (McNees et al., 2005) primer 
express software is used to design the primers and probes and subsequently 
synthesized by a company i.e. Applied Biosystems. 
 
1.8 Phylogenetic Analysis 
Phylogenetic analysis is the study of the evoluntionary relationship between 
organisms, it can be used in virology to examine closely related viral strains 
in an attempt to understand viral diversity, and further elucidate the 
transmission and spread of disease (McCormack and Clewley, 2002). 
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Nucleotide sequences are compared and the evolutionary relationship is 
constructed graphically in a phylogenetic tree. 
Phylogenetic trees can be constructed using distance or character based 
methods. Character based methods select trees based on the individual 
nucleotides at each position in the sequence alignment. The two main 
character based methods are maximum likelihood and maximum parsimony. 
Maximum Likelihood is generally the method of choice as it is character 
based and works on a model of evolution (McCormack and Clewley 2002). 
When constructing a phylogenetic tree, it is important that a representative 
of the common ancestor of the data set is included. This is generally done by 
using an outgroup. An outgroup sequence is one that is genetically related 
to, but not belonging to the group of interest (ingroup) (Wheeler,1990). To 
confirm the reliability of a phylogenetic tree, bootstrapping is performed. 
This is a random resampling process where the sequences are realigned 
repeatedly, generally 1000 times, to create the best fit tree. A value is 
calculated based on the frequency that a consistent branching pattern is 
observed. Values greater than 70% are thought to have strong bootstrap 
value and generally indicate that the position of the corresponding sequences 
on the tree is correct.  
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1.9 Aims 
To date, there has been limited investigation of polyomavirus reactivation in 
pediatric patients with renal transplants or with primary renal disease.  Given 
the association of polyomavirus reactivation with the use of immune 
suppressive therapies, we sought to investigate whether polyomavirus 
reactivation occurred in patients with pediatric kidney disease and if so how 
does this correlate with pediatric patients who are immunosuppressed for 
other reasons. 
 We assessed three separate pediatric patient groups who differed in the 
degree and type of immunosuppressive condition present. 
1) Pediatric patients with nephrotic syndrome (NS) 
2) Pediatric renal transplant recipients (RT) 
3) Pediatric patients with other immune compromise (IC) e.g. HIV infection, 
acute lymphocytic leukemia or heart transplantation. 
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The main aims of this project were to 
A) Determine the prevalence of polyomavirus viruria and viremia in  
     pediatric patients with nephrotic syndrome, patients who    
     have received a kidney transplant and otherwise    
     immunocompromised patients 
B) Determine presence of virus; BKV or JCV present in urine and blood 
samples by qualitative PCR. 
C) Determine amount and type of virus; BKV or JCV present in urine 
and blood samples by quantitative Real-time PCR and compare this to 
the qualitative results. 
D) Determine the type of polyomavirus present, BKV or JCV. 
E) Determine the sub-type of virus present by commercial genome 
sequencing. 
F) Determine race, gender and age association of the respective viruses. 
G) Compare the patient groups for type and amount of virus present. 
H) Establish mean amounts of virus present in each sample. 
I) Look at trends in virus excretion in the urine of patients over time. 
J) Determine if the immunotherapy a patient is being treated with has 
    any effect on the amount of polyomavirus detectable in the urine. 
K) Compare a patient’s white cell count with the viral loads in their 
     urine. 
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Hypothesis:  Polyomavirus viremia and viruria is more common among 
patients after renal transplantation (RT) than in those with nephrotic 
syndrome (NS). 
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2. Materials and Methods 
 
2.1 Study Subjects 
Three categories of pediatric patients were analyzed in this study. Some 
patients had nephrotic syndrome (NS), some had had a renal transplant and 
the other group of patients were immune compromised (IC) due to another 
disease e.g. HIV infection, acute lymphocytic leukemia or heart 
transplantation. Nephrotic syndrome is a disorder where the kidneys have 
been damaged due to inflammation, causing them to leak protein from the 
blood into the urine. In children a condition called minimal change disease 
(MCD) accounts for 95% of nephrotic syndrome cases and the other 5% is 
usually due to a condition called focal segmental glomerulosclerosis (FSGS) 
which is a disease that involves scarring of segments of the glomerlus. 
Generally treatment of nephrotic syndrome involves immunosuppressive 
therapy and we sought to compare BKV viral excretion in these patients 
with those who had had renal transplantation. Our third group patients were 
immune suppressed but their conditions were not associated to the kidney 
e.g. HIV and acute lymphocytic leukemia and so it would be interesting to 
see if their immunosuppression was also leading to reactivation of the virus. 
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2.2 Study Enrollment and Sample Collection 
One hundred and twenty-five patients were enrolled between February 2000 
and October 2005. Enrollees were from three patient populations; 
1) patients with nephrotic syndrome (NS) (n=81) 
     2) renal transplant recipients (RT) (n=16) 
     3) patients with other immune compromise (IC) e.g. HIV infection, acute 
         lymphocytic leukemia or heart transplantation. (n=28) 
Urine and blood samples were collected at the time of routine clinic visits. 
Blood specimens were only obtained for study purposes when blood was 
being drawn for clinical purposes. Five milliliters of whole blood was 
obtained by peripheral venipunctures, using aseptic techniques, into sodium-
heparin collection tubes. Samples were allowed to settle for 2 hours and 
plasma was removed as was the buffy coat interphase. Urine samples were 
obtained in sterile collection cups and stored at 4oC for < 12hrs. Aliquots of 
1ml of urine and plasma were cyropreserved at -70oC prior to analysis. Some 
urine samples were subjected to low speed (2000g) centrifugation for 10 min 
at room temperature, to pellet cellular material. The supernatant was 
separated from the pellet, both of which were stored at -70oC and both were 
tested. Sample identification included the laboratory accession number, the 
date of collection, and the patient’s date of birth.  
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For avoidance of cross-contamination we maintained strict protocol 
measures throughout the study, including the use of separate, plasmid-free 
rooms, and centrifuges for processing of clinical samples, isolation of DNA, 
PCR set-up and PCR analysis. 
 
2.3 Prospective medical record review 
To assess the demographic and medical factors that may be associated with 
polyomavirus excretion in this pediatric population, approval was obtained 
from the Institution Review Board for Human subjects at Baylor College of 
Medicine, to review the medical records of patients whose blood and urine 
were tested. Specific data (gender, race/ethnicity, medication, evidence of 
immune compromise and medical history) was sought from each chart using 
an electronic data-collection form. This work is ongoing at present by 
Dr.Vanchiere and his group. 
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2.4 DNA Extraction 
 
Materials 
MagNApure-LC Instrument (Roche Applied Science, Indianapolis, IN) 
automated nucleic acid extraction platform. 
MagNa Pure LC (Roche Applied Science, Indianapolis, IN) Total Nucleic 
Acid Isolation Kit. 
MagNA Pure LC DNA disposables (pipette tips, holders, reaction and 
sample cartridges, reagent tubs and lids). (Roche Applied Science, 
Indianapolis, IN) 
 
Method 
200µl of sample (urine or blood) was added to sample cartridge and placed 
on the MagNA Pure LC instrument. MagNA pure LC Total Nucleic acid 
isolation kit reagents and disposables were placed on instrument as per 
instructions on screen. The magnetic glass particle solution was vortexed 
prior to use and added to instrument only after all other reagents and 
disposables were in place. Instrument was started with an extraction time of 
approx 3hrs. Instrument was checked at regular intervals for faults. 
Nucleic acids bound to the silica surface of the glass beads due to chaotropic 
salt conditions and the high ionic strength of the lysis binding buffer. 
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Purified nucleic acids were eluted at an elevated temperature and an elution 
volume of 100µl was transferred to a sterile cartridge and stored at -20ºC 
until needed. A negative control was included in each extraction run and 
consisted of 200µl of PCR grade water. 
 
2.5 Qualitative PCR  
 
Materials 
DNA polymerase (Ampli-Taq DNA Polymerase, Applied Biosystems, Inc., 
Foster City, CA) 
1 x PCR reaction buffer containing MgCl2, final concentration 1.5mM 
(Applied Biosystems, Inc.) 
200 µM for dNTPs (Promega, Madison, WI) assembled in a final volume of 
50µl.  
PYV.fr/PYV.rev primers (Appendix II). Amplify a 173-182 bp portion in the 
amino terminus of the T- antigen gene of BKV, JCV and SV40. 
Regulatory region primers specific for BKV (Appendix II) 
VP1 region primers for BKV (Appendix II).Plasmid clones of pBKV- strain 
Dunlop- 1 (Seif et al., 1979) 
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Method 
Total nucleic acid was extracted from 200µl of whole urine, urine pellets, 
serum, plasma or buffy coats using the MagNApure-LC (Roche, 
Indianapolis, IN) automated nucleic acid extraction platform as directed by 
the manufacturer. Extracted DNA was resuspended in 100µl of elution 
buffer of which 10µl was used for each PCR reaction. Samples were tested 
by qualitative PCR with primers PYV-for and PYV rev (Bergsagel et al., 
1992) that detect a 178-183bp region of the T-antigen gene in JCV, BKV 
and SV40 (Appendix II) 
PCR reaction components were mixed to a final concentration of 0.5-1µM 
for primers, 0.05-0.1 U/µl for heat stable DNA polymerase (Ampli-Taq 
DNA Polymerase, Applied Biosystems, Inc., Foster City, CA), 1 x for PCR 
reaction buffer containing MgCl2, final concentration 1.5mM (Applied 
Biosystems, Inc.), and 200 µM for dNTPs (Promega, Madison, WI) 
assembled in a final volume of 50µl. Conditions for PCR amplification 
using the PYV.fr/PYV.rev primers (Appendix II) were: 45 cycles of 
denaturation at 96oC for 30secs, annealing at 60oC for 30sec, and extension 
at 72oC for 45secs (Bergsagel et al., 1992, Lednicky et al 1997). Plasmid 
clones of pBKV- strain Dunlop- 1 (Seif, 1979) were used as positive 
controls for PCR reactions. All plasmid stocks had been previously prepared 
in the lab using the EndoFree Plasmid Maxi Kit (Qiagen) (McNees et 
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al.,2005). A standard graph was made by amplifying serial dilutions of the 
BK human polyomavirus viral DNA plasmid control containing the entire 
BKV genome (Dunlop-strain pUC-19), (Seif et al., 1979). The plasmid 
concentrations plotted ranged from 1 to 107 genomic copies. The negative 
control consisted of 50µl RNase free water. 
Samples that produced appropriate sized DNA amplimers with PYV.for and 
PYV.rev primers, as determined by direct visualization on ethidium 
bromide-stained agarose gels, were further tested using primers for the BKV 
regulatory region and VP1 region (Appendix II). These primers were 
previously designed in the lab using primer express software and synthesis 
by Applied Biosystems (Vanchiere et al., 2005). 
Conditions for PCR amplification using the regulatory region primers were: 
45 cycles of denaturation at 96oC for 30 sec, annealing at 63oC for 30 sec, 
and extension at 72oC for 45 sec (Lednicky et al 1997). 
The limit of detection for this assay is 1000 copies/ml of plasma or urine.  
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2.6 Agarose gel Electrophoresis 
 
Materials 
Agarose Powder, Molecular grade Promega 
Combs 
Pipettes and tips 
5 X TBE (Tris borat EDTA) 
Distilled water 
Ethidium Bromide 10mg/ml Sigma 
Blue loading dye Promega 
100 base pair DNA ladder 0.13µg/µl Promega 
Transilluminator 
Power Supply 
Digital camera 
Microwave 
Large and mini electrophoresis tanks 
 
Method 
12g/800ml (1.5g/100ml) of agarose powder was weighed on the balance. To 
prepare 1 X TBE running buffer, 100ml of 10X stock TBE buffer was 
poured into a 1 liter graduated cylinder and made up to 1 liter with deionised 
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water and mixed to give a homogenous solution. 800mls of TBE buffer was 
then added to the agarose powder in a beaker and microwaved until the 
solution was clear. Solution was then allowed to cool slightly before 
addition of ethidium bromide. 1.25µl/25ml of ethidium bromide was added 
in a fume cupboard and mixed to give a homogenous solution. The agarose 
solution was then poured slowly into a gel mould, carefully to avoid 
bubbles. Combs were placed at regular intervals through gel. Gel was 
allowed to cool for over an hour and then placed in an electrophoresis tank. 
TBE buffer was poured into the tank until the gel was completely covered 
and the combs were removed. 5µl of loading dye was added to the samples 
and to the 100bp DNA ladder size marker. 20µl of the mixture was added to 
each well and the power supply was connected to the tank with the DNA at 
the negative electrode (cathode). DNA is negative and will run towards the 
positive electrode (anode). Voltage was set to 100V and run. The gel was 
then visualized using an ultraviolet transilluminator. 
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2.7  Real-time Quantitative PCR 
Materials 
PRISM 7000 Sequence Detection System (Roche, Applied Biosystems) 
100nM of TaqMan FAM-MGB probe 
25ul of the 2 x TaqMan Universal PCR master mix (Roche, Applied 
Biosystems, New Jersey USA) 
900nM (each) forward and reverse primers (Appendix I) 
Positive displacement pipettes and barrier tips 
10μl of the test DNA 
Standard plasmid dilutions 
Microcentrifuge 
Sequence Detection System software 
Method 
In parallel with qualitative PCR, JCV-specific and BKV-specific 
quantitative PCR analysis was performed on all extracted DNA’s as 
described previously (McNees et al., 2005). In this project the primers and 
probes were previously designed (Bergsagel et al., 1992) to detect sequences 
in the conserved N-terminal region of the Large T-ag gene for each 
polyomavirus. The Large T-ag sequences of the BKV, JCV and SV40 share 
considerable homology so primer and probe designs are chosen to maximize 
the differences among the sequences in this region to eliminate the 
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possibility of cross reactivity. The oligonucleotide sequence and 
corresponding nucleotide positions are shown in (Appendix I). 
Quantitative real-time PCR assays were performed using the PRISM 7000 
Sequence Detection System (Applied Biosystems) according to the 
manufacturer’s recommendations. PCR amplifications were performed in a 
reaction volume of  50μl containing 100nM of TaqMan FAM-MGB probe, 
25ul of the 2 x TaqMan Universal PCR master mix (Applied Biosystems), 
and 900nM (each) forward and reverse primers.  
 
 Preparation of Real Time PCR Cocktail Mix 40µl per well 
                                                     1X                  100X 
1) 2 X Taq Man Master Mix (25µl)           2500µl 
2) Primer 1                            (1µl)               100µl 
3) Primer 2                            (1µl)               100µl 
4) Probe                                 (1µl)               100µl 
5) Gibco Water                      (12µl)           1200µl 
 
Table 2.1: Components of Real Time cocktail mix 
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PCR reactions were prepared in the PCR Clean Rooms Core Facility using 
positive displacement pipettes and barrier tips. 10μl of the test DNA or 
standard plasmid dilutions were added in duplicate outside the core facility.  
Thermal cycling was initiated as follows: 50oC for 2 min, denaturation step 
of 10 min at 95oC, followed by 40 cycles of denaturing at 95oC for 15secs, 
followed by annealing and extension at 60oC for 1 min at the end of which 
fluorescence was read. Real-time PCR amplification data were analyzed by 
the Sequence Detection System software provided by the manufacturer.  
By amplifying serial dilutions using the BK human polyomavirus 
quantitated viral DNA plasmid control containing the entire BKV genome 
(Dunlop-strain pUC-19), (Seif et al., 1979) and  JCV-Mad-1 strain (Frisque 
et al., 1984) the sensitivity of the quantitative PCR procedure as a minimal 
we established a detection level of 100 copies/ml , while for qualitative PCR 
it was 1000 copies/ml. Standard curves for the quantification of BKV and 
JCV were constructed using serial dilutions of the Dunlop-strain pUC-19 
plasmid and the pJC-MAD-1 for JCV. The plasmid concentrations plotted 
ranged from 1 to 107 genomic copies per RT-PCR. All patient samples were 
tested in duplicate, and the numbers of BKV viral copies were calculated 
from the standard curve. Data were expressed as copies of viral DNA per 
milliliter of urine or plasma. 
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2.8 Purification and sequencing of PCR Product 
 
Materials 
QIAquick® PCR Purification kit 250. (QIAGEN Sciences, Maryland 20874 
USA). 
Pipettes and tips 
50µl storage tubes 
 
Method 
Products of the correct length for the VP1 capsid protein and amplicons of 
the VP1 gene (50 μl for each sample) were purified according to the 
manufacturer’s instructions using QIAquick® PCR Purification kit 250 
(QIAGEN Sciences). The eluted PCR product was stored in sterile labelled 
tubes before being sent for sequencing. 
DNA sequencing was carried out by Lone Star Labs, Inc. (Houston, TX) 
utilizing the ABI Prism Automated DNA sequencer 377XL and Big Dye 
Terminator Ready Reaction Cycle Sequencing Kit (Applied Biosystems, 
Inc) according to the manufacturers directions.  
Sequences were viewed and corrected using the program. Chromas version 
2.32 (http://www.technelysium.com.au/chromas.html). A maximum 
likelihood tree was constructed using PAUP* version 4.0 (Swofford) and 
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Modeltest (Posada). Bootstrap resampling was carried out for 1000 
replicates of the data set. 
 
 
2.9 Statistical Analysis 
Statistical analysis was performed using Microsoft excel (Microsoft 
Corporation, Redmond, WA). Data was analyzed using the chi-squared (x2 ) 
or student t-test. A p-value < 0.05 was considered statistically significant. 
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3. Results 
This study aimed to examine the prevalence of polyomavirus viruria and 
viremia in pediatric patients with nephrotic syndrome and patients who have 
received a kidney transplant. To accomplish this we set about carrying out a 
longitudinal prospective study of one hundred and twenty five patients 
enrolled over a five year period between February 2000 and October 2005 
from Texas children’s hospital. Over this time there were 554 patient 
encounters in total. The median age of the patients was 11.7 years and the 
range was 6 months to 25 years. An average of 7.4 samples was collected 
per patient. A total of 388 urine specimens and 280 blood samples collected 
over time, were examined from the 125 patients enrolled. DNA was 
extracted from all samples received by MagNA pure extraction and stored at 
-70oC in preparation for further analysis. 
The first objective of this project was to determine whether there were any 
polyomaviruses present in the samples. To accomplish this it was decided to 
firstly qualitatively test the samples for the presence of polyomavirus. 
Qualitative PCR (Fig 3.1) was performed using primers PYV-for/PYV-rev 
which amplify a 173-182 bp region in the amino terminus of the T-antigen 
gene of BKV, JCV and SV40 (Appendix II). 34 samples out of a total of  
933 samples (blood and urines including duplicate blind samples) tested 
positive for a 173-182 bp product (T-antigen), however this information is 
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uninformative as regards which virus (BKV, JCV or SV40) was present in 
the sample. All 34 positive samples were from urines. 
 
                                    Qualitative PCR agarose gel 
                       S1 S2 S3 S4 S5             S6                                S7 S8 S9 
  M 
 
 
 
Fig 3.1. Qualitative PCR using primers PYV-for/PYV-rev which amplify a 173-182 bp 
region in the amino terminus of the T-antigen gene of BKV, JCV and SV40 (Appendix II). 
Samples S1-S9 all showing correct size product for T-antigen. S5 shows a number of 
different bands, however, because there is a band of the correct size present this sample 
is deemed positive.  
 
Next 933 urine and blood samples were tested by real-time PCR for the 
presence of BKV or JCV using forward and reverse primers that were 
designed to amplify viral genomic regions for the large T-ag genes of BKV 
or JCV (Appendix I).  
51 patient samples were positive by real-time PCR for BKV and 31 patient 
samples were positive for JCV. It was then decided to try to detect BKV by 
qualitative PCR using different primers, VP1 primers (Appendix II) and 
180bp
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regulatory region primers (Appendix II). 34 samples were positive using 
VP1 primers and only 7 were positive using regulatory region primers. 
Therefore it became clear that real-time PCR was the most informative 
method of detection. Since real-time PCR gave the most sensitive results it 
was decided only to rely on real-time results for detection of virus in 
samples. And all results in this section reflect these. 
To assess the real-time assay for reproducibility we randomly included some 
samples on 2 or more occasions and tested them blindly. There were 139 
samples tested in this way and 92% of the time the same result was found for 
the same sample tested in duplicate.  
 
 % reliability of assay =            True Negatives        =          117      = 92% 
                                 True Negatives + False Negatives     117+10                         
 
117 samples were negative each time they were blindly tested for BKV, 12 
samples were positive each time and 10 samples were positive sometimes 
and negative sometimes. For JCV 125 samples were negative each time they 
were tested 9 samples were positive each time and 5 samples were negative 
sometimes and positive sometimes. Table 3.1 shows the variability of the 
real-time assays. 
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139 Samples Tested in duplicate by Real-time PCR 
9
12
POS/POS
125
117
NEG/NEG
5
10
NEG/POS
JCV 
BKV
Duplicates* ( Total 139)
*between 2 - 5 samples
 
 Table 3.1 Real time assay variability found in duplicate samples. Samples were blindly 
tested on 2 or more occasions. 
 
On analysis of our real-time data it became clear that almost all the positive 
samples for polyomavirus were in urine (Table 3.2) and it was very unlikely 
that we would find the virus in blood (Table 3.3). Therefore firstly we 
looked at virus excretion in the urine of patients in each subgroup, nephrotic 
syndrome (NS), renal transplant (RT) and secondary immunocompromised 
(IC).  
Overall we found that polyomavirus DNA could be detected in the urine of 
43 (42.1%) of 102 patients who gave urine samples. 28 patients (27.4%) 
were positive for BKV and 11 patients (10.7%) were positive for JCV.  4 
patients (3.9%) were positive for both viruses (Table 3.2). 
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BKV and JCV Real-time results for urine samples taken from    
the three study populations  
                                                                            
Urine Samples 
 (n= 388) 
 Total 
BKV 
(+) 
JCV 
(+) 
BKV & 
JCV (+) 
Nephrotic syndrome  74 
18 
(24.3%) 
7 
(9.5%) 
3 
(4.0%) 
Renal transplant 16 
6 
(37.5%) 
4 
(25%) 
1 
(6.3%) 
Other Immune 
Compromise 
12 
4 
(33.3%) 
0 0 
   102 
28 
(27.5%) 
11 
(10.7%) 
4 
(3.9%) 
 Table 3.2.Urine samples only from the three patient sub-groups.                  
Examining the results by patient subgroup revealed that polyomavirus 
excretion in general (JCV or BKV) was significantly more common among 
RT patients than NS patients (11/16 vs. 28/74, p=0.0005). 
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JCV viruria was more common among RT patients (31%) compared to NS 
patients (13%)  (5/16 vs. 10/74, p= 0.02, x2 test), and a similar finding was 
observed for BKV, RT patients (43%) compared to NS patients (28%).  
(7/16 vs. 21/74, p=0.09, x2 test). However on analysis the result for BKV 
was not statistically significant between the two groups. 
However it can be seen that polyomavirus reactivation in the urinary tract 
was more common after RT than among subjects with NS.  
On examination of blood for the presence of polyomaviruses the results were 
very different to that of urine. We looked for the presence of virus in the 103 
patients that we had blood samples on. Table 3.3 shows the amount of virus 
found in the 280 bloods tested. Only on two occasions was a positive result 
found on a real-time assay. The copy number found was < 3000 
genomes/per ml of blood which was a very low copy number compared to 
the copy number’s found in urine, 500-1.5*1010 copies/per ml (Table 3.4). 
The rare occurrence of virus to be found in blood is what was expected as 
none of the patients had developed BKVN, and a viremia usually precedes 
development of this disease. BKV viremia was observed in only 1 of the 15 
RT patients we had blood samples from and 1 of the 66 NS patients that we 
had blood samples on.  Both patients had BKV viral loads <3000 genome 
copies/ml of plasma. 
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 Blood samples tested by RT-PCR in patient subgroups 
002103Total
00022
Other Immune 
Compromise
0
0
JCV
(+)
0
0
BKV & 
JCV(+)
15
66
Total
1*Nephrotic Syndrome
1*Renal Transplant
BKV
(+)
Blood samples
(n= 280)
 
      Table 3.3.Blood samples only. * <3,000 ge/ml       
                     
This study also sought to determine the viral copy numbers in the samples. 
When conducting the real-time PCR a standard graph was made by 
amplifying serial dilutions of the BK human polyomavirus viral DNA 
plasmid control containing the entire BKV genome (Dunlop-strain pUC-19), 
(Seif et al., 1979) and JCV-Mad-1 strain (Frisque et al., 1984). The plasmid 
concentrations plotted ranged from 1 to 107 genomic copies therefore we 
could compare the real-time results on our samples to the standard graph and 
determine the viral copy number in each sample. 
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We examined the viral copy numbers of BKV and JCV in RT patients 
compared to NS patients. The mean amount of virus, BKV and JCV 
(genome per ml of urine) found in patients with NS versus those who have 
had RT was not found to be statistically different (Fig 3.2). The mean BKV 
and JCV viral loads in urine, respectively, were 7.7x107 ge/ml and 1.9x106 
ge/ml for subjects with NS and 1.5x109 ge/ml and 8.4x104 ge/ml for RT 
recipients (p>0.1 for BKV and JCV). 
   Mean amounts of virus excreted in patient sub-groups 
  
  
   
 
 
   
  Fig 3.2.Comparison of BKV and JCV viruria in study populations. The mean amount of 
either virus in not statistically different between patients with nephrotic syndrome 
compared to those who have had renal transplants. 
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The majority of patients supplied us with clinical samples everytime they 
visited the clinic over the period of this study. Therefore the presence of 
virus in these patients could be studied over various time points. We sought 
to determine if patients who have had renal transplants were more likely to 
excrete BKV in their urine consistently over time compared to the nephrotic 
transplant patients. Table 3.6 shows the patients whom we had 5 or more 
consecutive urine samples on. Some patients secreted BK virus in their urine 
sporadically which was when BKV was found in their urine samples < 30% 
of the time they gave a urine sample. And other patients secreted virus more 
consistently >/=50% of the time they gave a urine sample. These results 
indicated that the renal transplant patients were more likely to be consistent 
shedders of BKV (7/12) compared to nephrotic syndrome patients (7/72  
p= 0.0005).Again, when these results are correlated with 
immunosuppressive therapy they will give us more insight into the 
reactivation of BK virus. 
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Excretion of virus in patients on consecutive occasions 
72
Renal 
Transplant
(16 patients)
710
Nephrotic
Syndrome
(72 patients)
Consistent
excretion
Sporadic
excretion
Positive on >1 
occasion
>/=50%Consistent
<30%Sporadic
      
Table 3.4. Patients in whom Bk  virus was found to be shed in urine sporadically or 
consistently. Sporadic excretion was noted when patient excreted virus in less than 30% 
of their samples at separate clinic visits, while consistent excretion was noted in patients 
excreting virus in more than 50% of their samples. 
          
Another important part of this study was to look at the influence 
immunosuppressive therapy has on the amount of virus replication taking 
part in the body and therefore being secreted in the urine. For example Fig. 
3.3. shows a patient whose identification number is NS-005, viral shedding 
in urine over time.  
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           Timeline of BK excretion in patient NS-005 
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Fig 3.3. Timeline of BKV excretion in patient NS-005 (identification number). Amount of 
virus found in the patient’s  urine at different times is shown. 
 
The first urine sample from the patient on 19th of January 2005 shows that 
the patient was excreting a large amount of virus in their urine, 1x109 
genomes/ml, this dropped to 3x105 genomes/ml in July of the same year and 
then the amount of virus started to rise again toward the end of 2005. When 
we compare this to the medication the patient was receiving at the time we 
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can see that when the patient gave the first urine sample on 19-01-05 he/she 
were being medicated with cyclosporine and 30mg of steroids. This 
immunosuppressive therapy may be the reason the virus was able to 
replicate unchallenged and the viral load reached 1x109 genomes per ml of 
urine. Then as the steroid dose reduced (19/04/05 20mg steroids) the viral 
load also decreased to 3x105 genomes per ml and steadily decreased to 5x102 
genomes per ml on the 19/07/05 when the patient ceased taking cyclosporine 
and the steroid dose was 20mgs. Then on the 29/11/05 their viral load started 
to rise again to 7x104 copies per ml and at this time the patient was not 
taking cyclosporine and their steroid dose was 10mg, therefore other host 
factors must be at play to keep the viral load in check in the body.  
This tells us that immunosuppressive status alone does not always correlate 
with a rise or fall in viral load, other parameters must be looked at to see 
how the patient is coping with the virus. Looking at parameters such as T 
cell responses particularly CD8 T cells may give a clinician a better idea of 
how the patient is dealing with the virus. Immunological tests such as 
proliferation assays and functional assays of T cell subsets may be used in 
the future along side RT-PCR for viral load to build a picture of the bodies 
response to the virus and help clinicians in deciding on treatment of these 
patients.  
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Patient NS-004 also is a good example of the effect immunosuppressive 
therapy can have on the ability of a virus to replicate. Patient NS-004 first 
gave a urine sample on 13/11/00 and had no virus present in his/her 
consecutive urine samples until 24/11/04 when he/she began treatment with 
60mg of steroids. At this time a viral load of 1.3x106 copies of BKV was 
detected in his/her urine, indicating that as the patient became 
immunosuppressed, his/her ability to maintain the virus in latentcy was 
dimished and the virus replicated freely. When the patient’s steroid dose was 
decreased to 20mg a day the virus was no longer detectable, indicating the 
patient’s body regained its capacity to deal with virus. However the 
immunosuppressive therapy will not always have this effect on every 
patient. For example patient NS-032 was being treated with 60mg of steroids 
for 2 months and had no virus detectable in the urine, therefore as previously 
stated other unique host factors must come into play to allow the body to 
maintain the virus in latency. It is possible that patient NS-032 had a more 
effective T cell cytotoxic response to the virus and only by performing 
immunological assays can these other host parameter’s be monitored. 
 
 
Table 3.5 shows gives an example of patient NS-005 all other information, 
including immunosuppressive therapy on each patient is in Appendix IV. 
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I.d. 
Number 
Date of 
urine 
sample 
BKV viral 
Load 
ge/ml 
Immuno-
suppressive 
therapy 
Steroids Dose 
mg 
WCC 
109/ml
NS005 19/01/05 1x109 Cyclosporine Yes 30 13.2 
 19/04/05 3x105 Cyclosporine Yes 20 7.9 
 28/06/05 1x105 Nil Yes 20 7.9 
 19/07/05 5x102 Nil Yes 20 9.3 
 29/11/05 7x104 Nil Yes 10 ----- 
 
Looking at viral load in relation to the patient’s white cell counts, patient 
NS-055 gives a good example of when the patient’s white cell count drops 
there is an increase in their viral load. Patient NS-055 had 11.66 WCC/10ul 
on the 28/10/02 and no virus in their urine. Then on 24/01/05 they had 1x104 
copies of JCV in their urine while their WCC had dropped to 6.71 
WCC/10ul. Although decreasing white cell counts don’t definitively mean 
that there will be a corresponding rise in viral load it can be used in 
conjunction with other parameters to access a patient’s immuno-status and 
ability to fight the virus. 
As the epidemiology of polyomaviruses is only beginning to be studied at 
the moment we sought to look at the influence if any, of virus excretion, in 
patients of different ages, genders and ethnicities. Patients of a variety of 
different ages were enrolled from 6 months to 29 years. 67 males and 58 
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females took part and they came from a variety of different ethnic 
backgrounds as outlined in (Table 3.6). 81 patients had nephrotic syndrome, 
16 patients had renal transplants and 28 patients had secondary immune 
compromise (leukemia, heart transplant or HIV). 
 
  Demographics of the 3 patient subgroups in the study 
      
11624Caucasian
9321African-
American
Ethnicity:
7728Hispanic
8
44 Male
37 Female
10.4
81
Nephrotic 
Syndrome
0
6 Male
10 Female
18.1
16
Renal
Transplant
1Asian
17 Male
11 Female
Gender
8.1Median Age
28# Enrolled
Immune 
compromised
 
     
 
    
 
 
 
     Table 3.6 Patient demographics. The breakdown of gender and ethnicity in each     
    patient subgroup is similar.        
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As the prevalence of BKV and JCV in different age groups has previously 
been studied (Shah et al, 1973) we sought to compare our results with what 
is already known. The mean age of our patients when excreting 
polyomaviruses was 12.2 years (range, 3.2-31.2 years), which was not 
statistically different from the mean age of those not excreting 
polyomaviruses. Analysis of the age distribution of children with detectable 
polyomavirus excretion revealed the prevalence of BKV to be 20% (3/15) 
among patients 0-4 years old, 25% (10/40) among patients 5-9 years old,  
32% (12-37) among patients 10-14 years old, 25% (7/28) among patients 15-
19 years old and 14% (1/7) among patients 20-24 years old. Whereas the 
prevalence for JCV was 0% (0/15) among patients 0-4 years old, 10% (4/40) 
among patients 5-9 years old, 13% (5/37) among patients 10-14 years old, 
11% ( 3/28) among patients 15-19 years old and 57% (4/7) among patients 
20-24 years old ( Fig 3.4) . 
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Age Distribution of Polyomavirus excretion in urine 
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Fig 3.4.  Chart showing amount of virus excreted in the urine of different age groups. 
 
 
These results are consistent with previous studies on antibody prevalence 
(Fig 1.2), showing BKV to be more prevalent in the younger age groups and 
JCV more prevalent in the older (Shah et al., 1973). 
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We also sought to analyze our results to see if ethnicity had any influence on 
the excretion of BKV in urine. Evaluating BKV excretion in different ethnic 
categories indicated that in fact there was no statistical difference in the 
distribution of BKV among the different race/ethnicity categories (Fig 3.5). 
36% (13/36) Caucasians, 31% (8/26) African Americans, 31.5% (10/32) 
Hispanics and 12.5 (1/8) Asians were found who were excreting virus in 
their urine. (These numbers reflect ethnicities of patients who gave urine 
samples only and do not contain the total no. of people with different 
ethnicities in the study as some patients only gave blood samples). To note, 
we had a low number of Asian patients in this study so comparison with this 
population is uninformative. 
                                                 Ethnicity                                                                   
0%
5%
10%
15%
20%
25%
30%
35%
40%
Caucasian African-
American
Hispanic Asian
Race
%
 e
xc
re
tin
g 
B
KV
 in
 u
rin
e
Series1
 
Fig 3.5.Chart showing amount of virus being excreted in the urine of different races. 
Results indicate no statistical difference between different races.  
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Regards gender, we found that neither sex has more likelihood than the other 
for excretion of virus in urine. BKV was not more common in male patients 
in either sub-group (nephrotic syndrome or renal transplant) than in female 
patients in either sub-group (Fig 3.6). 15/44 males with NS were excreting 
virus compared to 9/37 females (P>0.1) and 4/6 males with RT were 
excreting virus compared to 5/10 females (P>0.1).  
  
Gender related excretion of BKV in patient sub-group 
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 Fig 3.6.Chart showing difference in BK virus excretion in the urine of male and female 
nephrotic syndrome patients versus male and female Renal Transplant patients. Results 
show no statistical difference between male and females. 
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Another objective of this project was to determine what strains of virus were 
present in our study population and access whether one strain appears to be 
more prevalent than another. As previously mentioned, different BKV 
strains can be identified based on the VP1 region and thus divided into 4 
genotypes: I, II, III, and IV. 
We sought to determine what strains were present in our patient population. 
Qualitative PCR for the VP1 region was carried out on all samples that were 
BKV positive by real-time PCR. There were 74 samples in total that were 
BKV positive so the DNA stored from the MagNA Pure extraction was used 
to amplify the VP1 region. Primers for the VP1 regulatory region (Appendix 
II) were used and after PCR amplification the PCR product was purified 
using QIAquick® PCR Purification kit 250 (QIAGEN Sciences). 
Amplification was only successful in 34 of these samples. The eluted PCR 
product was sent to Lone Star Labs, Inc. (Houston, TX) for sequencing. 
Sequences were viewed and corrected using the program. Chromas version 
2.32 (http://www.technelysium.com.au/chromas.html). A maximum 
likelihood tree was constructed using PAUP* version 4.0 (Swofford) and 
Modeltest (Posada). Bootstrap resampling was carried out for 1000 
replicates of the data set. 
 So far DNA sequencing data reveal that 4 samples were genotype 1a, 8 
were genotype 1b and 22 were not able to be determined due to poor 
Polyomavirus Excretion in Pediatric Renal Disease                                          Julie Moran 
____________________________________________________________________________________________________________ 
________________________________________________________________________ 66
sequencing reactions. The significance of these different stains has yet to be 
established yet it is known that BKV type I is the most prevalent serotype in 
the population (Jin et al., 1993). 
12 sequences are represented on the phylogenetic tree constructed in Fig. 
3.7. all cluster as genotype I sequences. This is consistent with previous 
publications stating that genotype I is the most prevalent BK virus strain 
worldwide. In addition, our results indicate that this strain type is endemic 
within our patient population. We included genotype I reference strains 
isolated from BK positive specimens from Japan, Boston, U.S. and 
Manchester (Table 3.7), confirming that the strains found within our patient 
group are also circulating throughout the world.  
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                   Accession numbers used in phylogenetic tree 
 
BKV Genotype Genbank accession No. 
III M23122 
II Z19536 
IV Z19535 
I Z19534 
I AY628225 
I Z19537 
I X56913 
I Boston AY628238 Hl 
I Japan AB301099 J2B2 
I Manchester DQ457407 Man2 
 
  
Table 3.7. BKV sequence accession numbers from genbank used in construction of the 
phylogenetic tree 
 
 
                                     
                                
 
Polyomavirus Excretion in Pediatric Renal Disease                                          Julie Moran 
____________________________________________________________________________________________________________ 
________________________________________________________________________ 68
                                    BKV Phylogenetic tree 
 
Fig 3.7. Maximum Likelihood Phylogenetic Tree of BKV-VP1 sequences detected in 
urine samples from 12 children in our study with Genbank representatives of the known 
sub-types I-IV with JC virus as the out-group. The numbers on the branches represent 
bootstrap values from 1,000 replicates. 
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All BKV genotype I strains were aligned against the reference BKV 
genotype I strain, Z19534. Two nonsynonymous mutations, unique to our 
patient sequences were detected. Valine to Leucine (T to A) and Glutamic 
acid to aspartic acid (G to C) (Fig 3.8) The significance of these mutations is 
as yet not known. 
 
 
Fig 3.8. BKV genotype I strain alignments 
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4. Discussion 
To date, there has been limited investigation of polyomavirus reactivation in 
pediatric patients with renal transplants or with primary renal disease.  Given 
the association of polyomavirus reactivation with the use of immune 
suppressive therapies, we sought to investigate whether polyomavirus 
reactivation occurred in patients with pediatric kidney disease. As both BKV 
and JCV are acquired during childhood, children undergoing 
immunosuppression may be particularly at risk for the complications of this 
infection. When the immune system is suppressed, patients are unable to 
mount a successful cell-mediated cytotoxic T cell response. This leads to 
uncontrolled viral replication and therefore a variety of problems for the 
patient. As previously mentioned BKV and JCV are ubiquitous in the human 
population and frequently reactivate during periods of immune suppression.  
The emergence of polyomavirus-associated diseases among renal and 
hematopoietic stem cell transplant recipients has highlighted the lack of 
knowledge of the natural history of BKV and JCV in humans.  In the 
pediatric population, in particular, immune suppressive therapy is commonly 
used as a treatment for primary renal diseases. BKVN has emerged as an 
important cause of post-transplant renal allograft loss, affecting ~5% of adult 
renal transplant (RT) recipients. BKVN is primarily due to the reactivation 
of BKV in the allograft kidney, although the pathogenesis of BKVN is 
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poorly understood.  While it is clear that BKV can be pathogenic in the 
setting of severe immune compromise, BKV reactivation alone is 
insufficient to cause BKVN, suggesting that host factors play a significant 
role in pathogenesis. 
This study sought to determine the prevalence of polyomavirus viruria and 
viremia in pediatric patients with nephrotic syndrome and patients who have 
received a kidney transplant. The hypothesis was that polyomavirus viremia 
and viruria is more common among patients after renal transplantation (RT) 
than in those with nephrotic syndrome (NS), and we found this to be true 
(Table 3.2). (11/16 vs. 28/74, p=0.0005). 
The results we have found in this study correlate well with what is already 
known about polyomavirus infection in pediatric renal disease (reviewed in 
Knowles et al 2001). Polyomavirus reactivation in the urinary tract is 
common among patients with nephrotic syndrome and particularly after 
renal transplantation (Table 3.2) The low prevalence of BKV viremia in our 
study population is likely a reflection of the use of reduced-intensity immune 
suppression after renal transplantation. However further study is necessary 
to determine the significance of polyomavirus reactivation in the pre-
transplant period. 
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One of the aims of this project was to determine whether there were any 
polyomaviruses present in the samples. To this end we qualitatively tested 
the samples for the presence of polyomavirus using conventional PCR 
(Section 2.2) using primers PYV-for/PYV-rev which amplify a 178-181 bp 
region in the amino terminus of the T-antigen gene of BKV, JCV and SV40 
(Appendix II). It was found that this method was not as sensitive as the real-
time PCR technique as half of the time it failed to detect the virus. Our real-
time results identified BK virus in 74 patient samples and JCV in 31 patient 
samples and the PCR for the T-ag (PYV.fr/PYV.rev) only identified the T-
ag of the polyomavirus in 34 patient samples. This may have been due to the 
low viral copy number found in some of these samples which the qualitative 
PCR would not have been sensitive enough to identify. 
Our real-time results are comparable to recent studies on BKV detection by 
real-time PCR. In a study by Pang et al., 2007 the limit of detection of BKV 
in urine was 300 copies/ml of urine and in our study the limit of detection 
was 100 copies/ml. In this study however a 309bp region of the VP1 region 
(different region to the region used for VP1 RT-PCR in our study) was 
amplified while in our study an area of the Large T-Ag was amplified 
(Appendix II). This may account for the slight difference in the limit of 
detection in the assays. 
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As explained in section 3 we also attempted detection of BKV by qualitative 
PCR using primers for the regulatory region (Appendix II) which identified 
the virus in 7 samples and the VP1 region (Appendix II) which identified the 
virus in 34 patient samples. The inability to amplify the regulatory region 
and/or VP1 region from some samples that yielded sequence-proven, virus-
specific PYV amplicons is consistent with findings in previous studies, and 
may be related to variations in viral load, the relative sensitivities of the 
different primer pairs, genetic differences among viral strains, and/or sizes 
of the amplicons produced. In a study by Zhong et al., 2007, they also 
identified problems when trying to amplify the noncoding control regions of 
BKV and found that these regions were amplified with lower efficiency then 
with other BKV typing regions. As the sensitivity of detection of the RT-
PCR assays was increased 10-100- fold compared to conventional PCR and 
agarose gel protocols it was decided to use only the real-time results for 
detection of BKV and JCV virus. 
Of note, an internal control was not included in this study. This would have 
been of use to control the assay for the quality of the MagNA pure extraction 
and also controlled for the reproducibility of the real-time reaction. Other 
studies have shown that spiking of samples with a virus not seen in humans 
and amplification of the sequence by real-time PCR can serve as an 
excellent internal control to show that your assay is working properly. In the 
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future a lot of clinical laboratories are moving towards introducing internal 
controls routinely into their assays. 
Regarding subtype of virus in our samples, the 12 samples that we got 
sequenced by a commercial lab (Lone star labs, Houston, TX) were all BKV 
genotype I, based on their VP1 region. This was expected as genotype I is 
the most prevalent genotype in the general population (Jin et al., 1993). We 
included genotype I reference strains isolated from BK positive specimens 
from Japan, Boston, U.S. and Manchester (Table 3.7) to compare our 
samples with and confirmed they were the same genotype circulating 
throughout the world. We also found a mutation from Valine to Leucine (T 
to A) and Glutamic acid to aspartic acid (G to C) (Fig 3.8) in 6 of our 
samples when we aligned them to our BKV reference strain Z19534. The 
relevance of this mutation is not immediately apparent to us and warrants 
further study. Since the mutation is on the VP1 protein which is a surface 
protein it is possible that the mutation has arisen in order to disguise the 
protein from the immune system. However the reason for this mutation at 
present is unknown. 
There were 933 samples from 125 patients processed in total for the 
presence of polyomavirus. All patient samples were tested using the RT-
PCR protocol described in section 2.4. This number reflects samples that 
were tested on more than one occasion. As mentioned all samples were 
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blindly tested so some samples were tested on two or more occasions. We 
found that a sample from the same date from a patient could only be 
demonstrated to be reproducible 92% of the time. This result may have been 
in part due to the nature of the sample. As previously mentioned some urine 
samples were subjected to centrifugation and the supernatant removed from 
the pellet. Therefore blinded aliquots from an independent sample may 
infact represent either the pellet or the supernatant, this may have lead to the 
inability to always get the same result when repeatedly testing a sample. To 
improve reproducibility a standard sample type only be tested. 
There were 388 urine samples in total and 280 blood samples and these 
reflect the samples that were taken from patients as they came to the clinic 
on different occasions throughout the time of the study.  Urine proved to be 
the sample that was more likely to contain virus as only on two occasions 
was virus isolated from blood. This finding was what we expected as none 
of our patients went on to develop BKVN and virus is usually apparent in 
the blood before development of the condition.  
To ensure accuracy we conducted this study blindly. We tested a total of 139 
random blind samples on more than one occasion to ensure reproducibility 
(Table 3.1) Also it is important to note, variation in the DNA sequences of 
the BKV strains detected so far in this study as compared to known 
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laboratory strains, show that laboratory contamination is highly unlikely as 
an explanation for our findings. 
Patients were enrolled from a variety of ethnic backgrounds. The numbers of 
patients enrolled from the different races were quite similar and therefore 
usually comparable. 33 were African-American, 41 were Caucasian and 42 
were Hispanic. However there were only 9 Asian patients enrolled so 
comparison of this race with the others was not possible. As regards the 
other races, they all were found to have similar excretion of BKV in their 
urine (Fig 3.5).When looking at the results with regards to age at excretion 
of BKV, it is clear that our results reflect what is already known about the 
antibody prevalence in the general population (Knowles et al., 2001). 
Typically that children are infected with the virus at a young age (approx 5 
years of age) and the incidence rises until they reach adulthood. Excretion of 
the virus in the urine is not indicative of a pathologic condition and occurs in 
many healthy individuals. In this study it was found that gender did not 
influence excretion of the virus in the urine and this is also consistent with 
previous studies (Nickeleit et al 2000). 
It can be seen in fig 3.2 that the mean amount of BKV was almost double 
that of JCV. The reasons for this are unclear at present. Also 74 of our 
patients had nephrotic syndrome and 16 had renal transplant and it is known 
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that reactivation of BKV occurs in renal disease while it is not known 
whether JCV shares this relationship. 
In this study we observed a higher level of polyomavirus, either BKV or 
JCV, viruria in renal transplant patients vs nephrotic syndrome patients 
(11/16 vs. 28/74, p=0.0005, x2 test). JCV viruria was more common among 
RT patients (31%) compared to NS patients (13%)  (5/16 vs. 10/74, p= 0.02, 
x2 test), and a similar finding was observed for BKV, RT patients (43%) 
compared to NS patients (28%).  (7/16 vs. 21/74, p=0.09, x2 test). However 
on analysis the result for BKV was not statistically significant between the 
two groups. Therefore it can be seen that polyomavirus reactivation in the 
urinary tract was more common after RT than among subjects with NS. 
11 out of 16 of the renal transplant patients we tested were excreting 
polyomavirus in their urine and almost half of these were consistently 
excreting virus everytime they gave a urine sample at their clinic 
appointments (7 out of 16, 44%). Reactivation of the virus in these patients 
was likely due to the high level of immunosuppressive therapy these patients 
were receiving to enable them to accept the graft. Disease was not apparent 
in any of these patients by the end of this study so the significance of the 
polyomavirus viral load in these patients is unknown. It is possible that once 
the patients are controlling the virus and maintaining the viral load under a 
certain level that the virus will cause no problems.  
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Our study also sought to correlate the amount and type of immune 
suppression a patient is taking with the amount of virus being excreted in the 
urine. We found that immunosuppression can not always be related to a rise 
in viral load in urine (Appendix IV). In some patients such as NS-005 we 
can see that viral load did seem to be related to the immunosuppressive 
therapy because as the the steroid dose reduced (19/04/05 20mg steroids) the 
viral load also decreased to 3x105 genomes per ml and steadily decreased to 
5x102 genomes per ml on the 19/07/05 when the patient ceased taking 
cyclosporine and the steroid dose was 20mgs. But then on the 29/11/05 their 
viral load started to rise again to 7x104 copies per ml and at this time the 
patient was not taking cyclosporine and their steroid dose was 10mg so this 
does not fit in with this theory. Therefore we hypothesize that other host 
factors must be at play to keep the viral load in check in the body. 
Parameters such as T cell responses particularly CD8 T cells should be 
monitored to give a better picture of how the patient is dealing with the 
virus. Also as we saw in patient NS-055 white cell counts is another helpful 
parameter to access the body’s ability to fight the virus. In patient NS-055 
(Appendix V) as their white cell count drops there is an increase in their 
viral load (24/01/05 they had 1x104 copies of JCV in their urine while their 
WCC had dropped to 6.71 WCC/10ul). However this relationship between 
WCC and viral loads is not apparent in all our patients (Appendix IV) 
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therefore immunological tests such as proliferation assays and functional 
assays of T cell subsets may be used in conjunction with RT- PCR, 
immunosuppressive therapy and white cell counts to give a more complete 
story for the treatment of the patient. 
Some studies have shown BKV reactivation can occur in 
immunocompromised transplant recipients and can cause BKVN. 1% to 
10% of kidney recipients develop BKVN (Hirsch et al., 2005), characterized 
by persistent graft dysfunction; of which about half will go on to lose their 
allografts (Nickeleit at al., 2000). Therefore it is imperative that the clinician 
stops BKVN developing by consistently monitoring their patients BKV viral 
loads. 
Although little is known about the clinical relevance of  polyomavirus 
infection in children, some case reports do exist documenting BKV 
nephropathy in pediatric kidney recipients (Vats et al., 2003) and in children 
with immunodeficiency (De Silva et al.,1995), (Rosen et al., 1983), 
(Cubukcu-Dimopulo et al., 2000). An example of a child who had an 
immunodeficiency that resulted in death by BKV was shown in a case report 
by Cubukcu-Dimopulo et al., 2000. He documented a rare case of a 14 year 
old boy with AIDS who developed a BKV infection in the lung and kidney 
and progressed to diffuse alveolar damage and death. The tubular epithelial 
cells in the kidney showed large, homogenous purple intranuclear inclusions 
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and in situ hybridization confirmed BKV as the pathogen. Therefore BKV 
infection should be considered as a differential diagnosis of opportunistic 
infections in patients with immunodefiencies also. 
There is limited knowledge available about the prevalence and effect of 
BKV in pediatric renal transplantation. However a prospective case 
controlled study of 18 Australian pediatric renal transplant patients showed 
an increase in BKV viruria in children with immunosuppression; 56% of 
patients were BKV IgG antibody sero-positive with a viruria rate of 33% by 
PCR compared with 39% sero-positivity and no viruria in the age matched 
controls (Haysom et al., 2004).  
The only other pediatric study to date to prospectively monitor both JCV and 
BKV polyomavirus in blood and urine was done in 46 pediatric renal 
transplant patients (Herman et al., 2004). In this study there were 2 patients 
with BKVN, 31% had BKV viruria, 17% had JCV viruria, and viruria was 
detectable prior to viremia. Our study in comparison found no renal 
transplant patients with BKVN, 37.5% had BKV viruria, and 25% had JCV 
viruria.  
BKVN is an important cause of progressive graft dysfunction in adult renal 
transplant recipients but very limited information has been published 
regarding BKVN specifically in the pediatric population (Hirsch et al., 
2002). In a study of adult renal transplants (Smith et al., 2004) they found an 
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incidence of 3.5% of patients developing BKVN which is similar to what 
has previously been reported in adults (Nickeleit et al., 2000). The incidence 
of BKVN in pediatric kidney transplants on the other hand has not been well 
defined. In a previous study an incidence of 3% of BKVN was found in a 
pediatric cohort where three cases of biopsy confirmed BKVN was 
presented among a cohort of 100 patients. This incidence of 3% correlated 
with the incidence previously reported in adult kidney transplant recipients 
(Nickeleit et al., 2000). At the time of completion of this study none of the 
patients had gone on to develop BKVN. 
More prospective studies will need to be carried out to elucidate the 
relationship between polyomavirus reactivation in pediatric renal 
transplants. 
There are several strengths and limitations to this study. The strengths 
include the large number of samples studied, the diversity in demographic 
background of the patients and the development of a PCR that detects all 
three human polyomaviruses in a single test. Limitations of this study 
include; silent infections in the children with different polyomaviruses and 
the fact that we cannot ascertain whether the observed excretions were 
associated with primary infection or viral reactivation. 
Also it is thought that another major cause of BKV nephropathy may be the 
transplantation of kidneys from BKV-seropositive donors into BKV-
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seronegative recipients. In our study the serological status of the patient pre-
transplantation is unknown so we can not hypothesis as to whether the BKV 
nephropathy constituted a primary or secondary infection. 
Currently, renal biopsy is the gold standard, for the diagnosis of 
polyomavirus nephropathy. For the pathologist this can present a problem as 
distinguishing BKV nephropathy from acute cellular rejection is inherently 
difficult, also considering that both conditions can coexist (Nickeleit et al., 
1999). RT-PCR to quantify BKV in urine offers a less invasive diagnostic 
tool for monitoring the possible development of BKVN compared to renal 
biopsy. Importantly to note the viral load can only be used as an indicator as 
a renal biopsy is always needed for the definitive diagnosis of BKVN. 
Several studies have evaluated the feasibility of using quantiatative PCR to 
monitor BKV-associated disease and suggest that correlations exist between 
viral shedding and disease states (Biel et al., 2000; Randhawa et al., 2004; 
Vats et al., 2003). Another advantage of RT-PCR is the ability to monitor 
the efficacy of antiviral drug treatments such as cidofovir (Vats et al., 2003).  
With the introduction of more potent immunosuppressive agents such as 
tacrolimus and mycophenolate mofetil, more BKV nephropathy in kidney 
transplant recipients is being documented (Binet et al., 1999). 
Management of BKV nephropathy is particularly difficult because the first 
therapeutic approach, is to reduce the amount of immunosuppression in the 
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patient to allow his/her body to mount an immune response to the infection. 
However this reduction in immunosuppression can lead to acute rejection of 
the kidney allograft, whose treatment in turn leads to reactivation of the 
virus. Therefore the solution to this problem must come in the form of an 
antiviral agent. To date there is no universally accepted therapy however in a 
recent study by Vats et al, treatment with a low dose of cidofovir was seen to 
rapidly clear virus from the plasma and urine (Vats et al., 2003). However 
there is a need for controlled trials to be carried out before this will become 
an acceptable treatment. 
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5.Conclusion 
Our study shows that monitoring the polyomavirus viral load in the urine of 
patients by a quantitative PCR technique is a useful tool to help to monitor 
polyomavirus infection and therefore its subsequent treatment. BKV viruria 
was detected in 37.5 % of renal transplant patients, 24.3% of patients with 
nephrotic syndrome and 33.3% of patients who had a secondary 
immunocompromise. Thus showing us that BKV viruria is quite similar 
between our patient groups. The use of immunosuppressive therapy does not 
always contribute to BKV viruria, nor does the type or amount of 
immunosuppressant being administered. Therefore it can be hypothesized 
that a range of host factors must come into play when dealing with the virus 
in each individual patient.  
Analysis of viral DNA sequence data and clinical data on the patients in this 
study is ongoing in Dr Vanchiere’s group in Houston. Identification of 
different BKV strains by DNA sequencing will help in understanding their 
relative contribution to disease.  
Understanding the virologic and host factors that maintain BKV latency in 
immune competent subjects will pave the way for understanding the 
pathogenesis of BKV related diseases and allow for development of clinical 
strategies to prevent and treat BKV disease.  
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Publications
 
The findings of this project are being presented at the American Society of 
Nephrology meeting in San Francisco and will be submitted to International 
Journal of Nephrology, Dialysis and Transplantation. Submission will also 
be made to the Journal of Pediatric Nephrology. 
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Appendix 
I:    Primers and TaqMan probes for polyomaviruses 
 
BKV 4400  gggtcttcta ccttttcttttt ttttttgggt ggtgttgagt gttgagaatc 
JCV 4263    gggtcttcta cctttttttt ctttttaggt ggggtagagt gttgggatcc 
 
BKV          tgctgttgct tcttcatcac tggcaaacat atcttcatgg caaaataaat 
JCV           tgtgttttca tc---atcac tggcaaacat ttcttcatgg caaaacaggt 
 
BKV         cttcatccca tttttcatta aaggaactcc accaggactc ccactcttct   4549 
JCV          cttcatccca cttctcatta aatgtattcc accaggattc ccattcatct     4409 
 
Appendix I:  Primers and TaqMan probes for polyomaviruses. These were 
designed to amplify viral genomic regions shown for the large T-ag genes of 
BKV, and JCV. Regions used for primer sequences are highlighted by boxed 
text and the probe sequences are underlined. Nucleotide numbers 
are shown and sequences are from p- BKV strain Dunlop-1( Seif et al., 
1979) and JCV strain MAD-1 (Frisque et al., 1984).  
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II : Primers used in qualitative PCR analysis  
______________________________________________________________________________    
Primer                                                                                             Position     Amplicon (bp)   
Polyomavirus conserved sequence (T-antigens)                        virus-specific     173-182       
PYV.for 5’-TAG TGC CAA CCT ATG GAA CAG A-3’ 
PYV.rev 5’-GAA AGT CTT TAG GGT CTT CTA CC-3’ 
BK virus (BKV) regulatory region                                                                
BK1 5’-GGC CTC AGA AAA AGC TTC CAC ACC CTT  
ACT ACT TGA-3’                                                                               nt 50-85                                                                   
BK2 5’-CTT GTC GTG ACA GCT GGC GCA GAA C-3’               nt 415-391           355       
VP1 region                                                                                                           
327-1  5’-CAA GTG CCA AAA CTA CTA AT-3’                            nt 1630-1650     
327-2  5’TGC ATG AAG GTT AAG CAT GC-3’                             nt 1956-1936      327        
______________________________________________________________________________ 
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III Clinical characteristics of 102 children evaluated for BKV 
and JCV in urine samples 
 
                                                                              BKV viruria                JCV viruria                 Both 
 
Number of patients (n = 102)                                   28                               11                               4                                
Age, mean (range), years                          17.73 (3.2-31.2)       15.19 (8.5- 23.6)       17.38 (12.65- 21.5) 
Race/ethnicity 
      White (n = 36)                                                 12                                   2                                  1 
      African American (n = 26)                               7                                   3                                   1 
      Hispanic (n = 32)                                              8                                    4                                  2 
     Asian (n = 8)                                                      1                                    2                                  0 
Sex 
     Female (n = 45)                                                  12                                 7                                   3 
      Male    (n = 57)                                                  18                                4                                    1 
Immune compromise                                                
     Nephrotic syndrome (n = 74)                             18                                  7                                   3  
     Renal Transplant (n = 16)                                   6                                   4                                   1 
    2ndary Immune Compromise ( 12)                      4                                  0                                    0  
Viruria (copies/ml urine) 
      Median                                                             1.0*105                     1.0*104             
      Range                                                            500~1.5*1010             650~3.1*106 
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IV Table of  Patient immunosuppressive therapy 
 
I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
IC-001 ALL 18/02/2000 yes None None yes   
IC-001 ALL 08/12/2000 no None None None   
IC-002 OHT 24/02/2000 no no no no   
IC-003 OHT 24/04/2000 no None None None   
IC-003 OHT ?  no None None None   
IC-004 OHT 14/04/2000 no no no no   
IC-005 OHT 20/04/2000 no no no no   
IC-005 OHT 06/12/2000 no no no None   
IC-006 OHT 20/04/2000 no no no no   
IC-006 OHT 21/12/2000 no no no None   
IC-006 OHT 21/09/2004 yes yes yes None   
IC-006 OHT ?   no None None None   
IC-007 ALL 12/05/2000 no None None None   
IC-007 ALL 13/07/2001 no None None None   
IC-007 ALL ?   no None None None   
IC-011 HIV 08/08/2000 no None None None   
IC-011 HIV 09/02/2001 no None None None   
IC-011 HIV ?   no None None None   
IC-012 HIV 08/08/2000 no no no no   
IC-013 HIV 08/08/2000 no None None None   
IC-013 HIV  ?  no None None None   
IC-014 HIV 10/08/2000 no None None None   
IC-014 HIV 15/03/2001 no None None None   
IC-014 HIV 21/08/2001 no None None None   
IC-015 HIV 29/08/2000 no no no no   
IC-015 HIV 15/03/2001 no None None None   
IC-015 HIV 13/07/2001 no None None None   
IC-015 HIV         ?  no None None None   
IC-016 HIV 29/08/2000 no None None None   
IC-016 HIV 21/02/2001 no no no no   
IC-017 HIV 30/08/2000 no None None None   
IC-018 HIV 30/08/2000 no no no no   
IC-018 HIV 21/02/2001 no no no no   
IC-018 HIV  ?  no None None None   
IC-019 HIV 06/09/2000 no no no None   
IC-020 ALL 11/09/2000 no no no no   
IC-020 ALL 05/03/2001 no None None None   
IC-020 ALL ? no None None None   
IC-020 ALL ? no None None None   
IC-021 HIV 19/09/2000 no no no None   
IC-021 HIV 13/07/2001 no no no None   
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
IC-022 HIV 19/09/2000 no no no None  
IC-022 HIV 13/07/2001 no no no None  
IC-022 HIV 06/09/2001 no None None None  
IC-022 HIV 19/02/2003 no None None None  
IC-023 HIV 19/09/2000 no None None None  
IC-023 HIV 15/03/2001 no None None None  
IC-023 HIV 06/09/2001 no None None None  
IC-025 OHT 27/09/2000 no no no no  
IC-025 OHT 13/12/2000 no None None None  
IC-026 HIV  ?  no None None None  
IC-028 OHT 29/09/2000 no None None None  
IC-028 OHT  ?  no None None None  
IC-030 OHT 09/02/2001 no no no no  
IC-031 HIV 16/02/2001 no no no no  
IC-034 ALL 12/04/2001 yes None None yes 2.7 
IC-034 ALL 11/07/2001 no None None None  
IC-036 ALL 16/04/2001 yes None None yes 20 
IC-036 ALL 16/04/2001 yes None None yes 20 
IC-046 OHT  ?  no None None None  
NS-001 NS 06/09/2000 no None None None  
NS-002 NS 13/11/2000 yes no yes no  
NS-002 NS 12/04/2001 no None None None  
NS-002 NS 18/07/2001 no None None None  
NS-002 NS 25/09/2002 yes no yes yes 20 
NS-002 NS 07/04/2004 yes no yes yes 20 
NS-002 NS 28/07/2004 yes no yes yes 5 
NS-002 NS 28/12/2004 yes no yes yes 10 
NS-002 NS 02/01/2005 yes no yes yes  
NS-002 NS 19/04/2005 yes no yes yes  
NS-002 NS 07/11/2005 yes no yes yes 30 
NS-002 NS 28/02/2006 yes no yes yes 5 
NS-003 NS 13/11/2000 yes no no yes  
NS-003 NS 27/08/2001 no None None None  
NS-003 NS 29/08/2001 no None None None  
NS-003 NS 10/09/2001 no None None None  
NS-003 NS 25/09/2002 no None None None  
NS-003 NS 10/03/2004 yes None yes None  
NS-003 NS 19/01/2005 yes None yes None  
NS-004 NS 13/11/2000 yes no yes yes  
NS-004 NS 23/04/2001 no None None None  
NS-004 NS 21/05/2001 no None None None  
NS-004 NS 18/07/2001 no None None None  
NS-004 NS 14/08/2001 no None None None  
NS-004 NS 24/11/2004 yes no yes yes 60 
NS-004 NS 04/01/2005 yes no yes yes 60 
NS-004 NS 09/02/2005 yes None None yes 20 
NS-004 NS 06/04/2005 yes no yes None  
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
NS-004 NS 28/06/2005 yes no yes None  
NS-004 NS 20/07/2005 yes no yes None  
NS-004 NS 27/09/2005 yes no yes None  
NS-004 NS 07/11/2005 yes no yes yes 60 
NS-005 NS 13/11/2000 no no no no  
NS-005 NS 07/05/2001 no None None None  
NS-005 NS 09/07/2001 no None None None  
NS-005 NS 10/09/2001 no None None None  
NS-005 NS 14/01/2002 no None None None  
NS-005 NS 19/01/2005 yes None yes yes 30 
NS-005 NS 19/04/2005 yes None yes yes 20 
NS-005 NS 28/06/2005 yes None None yes 20 
NS-005 NS 19/07/2005 yes None None yes 20 
NS-005 NS 29/11/2005 yes None None yes 10 
NS-006 NS 13/11/2000 yes no yes yes 80 
NS-006 NS 14/01/2002 no None None None  
NS-006 NS 25/10/2004 no no no None  
NS-006 NS 31/01/2005 yes no yes no  
NS-006 NS 22/08/2005 no None None None  
NS-007 NS 02/12/2000 yes no yes yes  
NS-007 NS 31/01/2005 yes no yes yes  
NS-007 NS ? no None None None  
NS-007 NS ? no None None None  
NS-007 NS ? no None None None  
NS-007 NS ? no None None None  
NS-007 NS ? no None None None  
NS-007 NS ? no None None None  
NS-007 NS ? no None None None  
NS-007 NS ? no None None None   
NS-007 NS ? no None None None   
NS-008 NS 14/11/2000 no None None None   
NS-008 NS 27/08/2001 no None None None   
NS-008 NS 23/07/2002 no None None None   
NS-008 NS 02/12/2002 no None None None   
NS-009 NS 16/11/2000 no None None None   
NS-009 NS 14/05/2001 no None None None   
NS-009 NS 10/09/2002 no None None None   
NS-010 NS 04/12/2000 yes no yes yes   
NS-010 NS 28/02/2001 no None None None   
NS-010 NS 17/09/2001 no None None None   
NS-010 NS 04/09/2002 no None None None   
NS-011 NS 04/12/2000 yes no yes yes   
NS-011 NS 05/03/2001 no None None None   
NS-011 NS 14/01/2002 no None None None   
NS-011 NS 29/07/2002 no None None None   
NS-011 NS 24/02/2003 no None None None   
NS-011 NS 22/03/2004 no None None None   
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
NS-011 NS 24/11/2004 no None None None  
NS-011 NS 21/05/2201 no None None None  
NS-012 NS 05/12/2000 no None None None  
NS-013 NS 05/12/2000 yes no no yes  
NS-014 NS 01/12/2000 yes no no yes  
NS-015 NS 07/12/2000 yes no no yes  
NS-015 NS 16/10/2002 no None None None  
NS-015 NS 24/01/2005 no None None None  
NS-016 NS 18/09/2001 yes no yes no  
NS-017 NS 18/12/2000 yes no yes yes  
NS-017 NS 17/09/2001 no None None None  
NS-017 NS 16/01/2002 no None None None  
NS-017 NS 31/07/2002 no None None None  
NS-017 NS 10/01/2005 yes yes no no  
NS-017 NS 11/04/2005 yes yes no no  
NS-017 NS 15/08/2005 yes yes no None  
NS-018 NS 18/12/2000 yes no yes no  
NS-018 NS 27/08/2001 no None None None  
NS-018 NS 06/01/2004 yes None yes None  
NS-018 NS 05/07/2005 yes None yes unknown 10 
NS-018 NS 28/02/2006 yes None yes yes 15 
NS-019 NS ? no None None None  
NS-019 NS ? no None None None  
NS-020 NS 19/02/2001 no None None None  
NS-020 NS 05/03/2001 no None None None  
NS-021 NS 26/02/2001 yes no yes no  
NS-021 NS 22/07/2002 no None None None  
NS-022 NS 26/02/2001 no no no no  
NS-023 NS 28/02/2001 yes no no yes  
NS-023 NS 23/04/2001 no None None None  
NS-023 NS 01/08/2002 no None None None  
NS-023 NS 26/08/2002 no None None None  
NS-023 NS 03/02/2003 yes None None yes  
NS-023 NS 10/11/2004 yes None None yes 25 
NS-023 NS 12/01/2005 yes None None yes 20 
NS-023 NS 23/03/2005 yes None None yes 30 
NS-023 NS 13/07/2005 yes None None yes 15 
NS-023 NS 26/04/2006 yes None None yes 2 
NS-024 NS 05/03/2001 yes no yes no  
NS-024 NS 08/10/2001 no None None None  
NS-024 NS 12/10/2004 no None None None  
NS-024 NS 18/01/2005 no None None None  
NS-024 NS 05/07/2005 no None None None  
NS-025 NS 21/01/2003 no None None None  
NS-025 NS 26/02/2003 no None None None  
NS-025 NS 22/03/2004 no None None None  
NS-025 NS 20/12/2004 no None None None  
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
NS-025 NS 05/07/2005 yes None None yes 60 
NS-025 NS  ?  yes no no yes  
NS-026 NS 12/03/2001 yes no no yes  
NS-026 NS 23/04/2001 no no no None  
NS-027 NS 13/03/2001 no no no no  
NS-028 NS 27/03/2001 no no no no  
NS-028 NS 07/05/2001 no None None None  
NS-028 NS 01/10/2002 no None None None  
NS-028 NS 10/11/2004 yes no yes yes 33 
NS-028 NS 01/02/2005 yes no yes yes  
NS-028 NS 29/03/2005 yes no yes yes 45 
NS-028 NS 20/09/2005 yes no yes yes 45 
NS-029 NS 16/04/2001 no None None None  
NS-029 NS 07/05/2001 no None None None  
NS-030 NS 16/04/2001 yes no no yes  
NS-030 NS 10/09/2001 no None None None  
NS-030 NS 28/10/2002 no None None None  
NS-030 NS 15/11/2004 yes None yes None  
NS-030 NS 06/03/2006 yes None yes None  
NS-031 NS 07/05/2001 yes no yes yes  
NS-031 NS 28/08/2002 no None None None  
NS-031 NS 01/03/2004 no None None None  
NS-031 NS 24/08/2005 no None None None  
NS-032 NS 07/05/2001 yes no yes no  
NS-032 NS 09/07/2001 no None None None  
NS-032 NS 30/03/2004 yes no yes None  
NS-032 NS 22/12/2004 yes no yes None  
NS-032 NS 26/01/2005 yes no yes no  
NS-032 NS 29/03/2005 yes no yes None  
NS-032 NS 21/09/2005 yes no yes yes 60 
NS-032 NS 19/10/2005 yes no yes yes 60 
NS-032 NS 15/11/2005 yes no yes yes 60 
NS-032 NS 15/03/2006 yes no yes None  
NS-032 NS 25/04/2006 yes no yes None  
NS-034 NS 14/05/2001 yes no no yes  
NS-034 NS 22/03/2004 yes None None yes 25 
NS-034 NS 30/03/2004 yes None None yes 45 
NS-034 NS 29/09/2004 yes None None yes 20 
NS-035 NS 21/05/2001 yes no yes no  
NS-035 NS 01/10/2002 no no no None  
NS-035 NS 10/12/2002 no no no None  
NS-035 NS 14/03/2006 no None None None  
NS-036 NS 21/05/2001 yes no yes yes  
NS-036 NS 14/01/2002 no None None None  
NS-036 NS 19/08/2002 no None None None  
NS-036 NS 04/02/2003 no None None None  
NS-036 NS 19/07/2004 yes no yes yes 80 
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
NS-036 NS 05/11/2004 yes no yes yes 80 
NS-036 NS 18/07/2005 yes no yes yes 80 
NS-037 NS ? no None None None  
NS-037 NS ? no None None None  
NS-037 NS 07/06/2001 no None None None  
NS-037 NS 09/07/2001 no None None None  
NS-037 NS 10/09/2001 no None None None  
NS-037 NS 22/07/2002 no None None None  
NS-037 NS 24/02/2003 no None None None  
NS-037 NS 14/12/2004 no None None None  
NS-038 NS 06/06/2001 yes no no yes  
NS-038 NS 07/06/2001 no None None None  
NS-038 NS 06/07/2001 no None None None  
NS-038 NS 17/09/2001 no None None None  
NS-038 NS 10/12/2002 no None None None  
NS-038 NS 13/01/2003 no None None None  
NS-039 NS 16/07/2001 yes no yes yes  
NS-039 NS 10/09/2001 no None None None  
NS-039 NS 14/03/2003 no None None None  
NS-039 NS 19/03/2004 yes yes no yes 10 
NS-039 NS 01/02/2005 yes yes no yes 40 
NS-039 NS 10/08/2005 yes yes no yes 20 
NS-039 NS 19/09/2005 yes yes no no  
NS-039 NS 10/10/2005 yes yes no None   
NS-040 NS 16/07/2001 no None None None   
NS-040 NS 18/07/2001 no None None None   
NS-041 NS 13/08/2001 no None None None   
NS-041 NS 21/08/2002 no None None None   
NS-042 NS 14/08/2001 no None None None   
NS-042 NS 17/09/2001 no None None None   
NS-043 NS 14/08/2001 yes no yes yes   
NS-043 NS 01/08/2002 no no no None   
NS-043 NS 02/12/2002 no no no None   
NS-043 NS 01/12/2004 yes None yes yes 80 
NS-043 NS 14/02/2005 yes None yes yes 40 
NS-043 NS 28/03/2005 yes None yes yes 40 
NS-043 NS 05/07/2005 yes None yes None  
NS-043 NS 19/09/2005 yes None yes None  
NS-043 NS 05/12/2005 yes None yes None  
NS-044 NS 20/08/2001 yes no yes yes  
NS-044 NS 26/08/2002 yes None yes None  
NS-044 NS 28/10/2002 yes None yes None  
NS-044 NS 20/12/2004 yes None yes yes 20 
NS-044 NS 17/10/2005 yes None yes yes 20 
NS-044 NS 07/11/2005 yes None yes yes 20 
NS-045 NS 10/09/2001 yes no yes yes   
NS-046 NS 18/09/2001 no None None None   
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
NS-047 NS 18/09/2001 yes no no yes   
NS-047 NS ? no None None None   
NS-047 NS ? no None None None   
NS-048 NS 18/09/2001 yes no no yes   
NS-050 NS 08/10/2001 yes no yes no   
NS-051 NS 07/10/2002 yes no yes yes   
NS-051 NS ? no None None None   
NS-051 NS ? no None None None   
NS-051 NS ? no None None None   
NS-051 NS ? no None None None   
NS-051 NS ? no None None None   
NS-051 NS ? no None None None   
NS-052 NS 14/10/2002 yes no yes yes   
NS-052 NS ? no None None None   
NS-052 NS ? no None None None   
NS-053 NS 15/10/2002 yes no no yes   
NS-053 NS 11/02/2005 yes no yes None   
NS-053 NS 12/04/2005 yes no yes None   
NS-053 NS 29/11/2005 yes no yes no   
NS-054 NS 23/10/2002 yes no yes yes   
NS-054 NS  ?  no None None None  
NS-055 NS 28/10/2002 yes no yes yes  
NS-055 NS 24/02/2003 no None None None  
NS-055 NS 08/11/2004 yes no yes yes 20 
NS-055 NS 24/01/2005 yes no yes None  
NS-055 NS 12/07/2005 yes no yes yes 10 
NS-055 NS 17/10/2005 yes no yes yes 50 
NS-056 NS 14/01/2003 yes no yes no  
NS-057 NS 14/01/2003 no no no no  
NS-058 NS 22/01/2003 yes no no yes  
NS-061 NS ? no None None None  
NS-061 NS ? no None None None  
NS-062 NS ? no None None None  
NS-063 NS 04/02/2003 yes no yes yes  
NS-064 NS 11/02/2003 yes no yes yes  
NS-064 NS ? no None None None  
NS-064 NS ? no None None None  
NS-065 NS ? no None None None  
NS-065 NS ? no None None None  
NS-065 NS ? no None None None  
NS-066 NS ? no None None None  
NS-068 NS 26/02/2003 yes yes None yes 20 
NS-069 NS 02/03/2004 yes None None yes 60 
NS-069 NS 14/12/2004 no None None None  
NS-070 NS 03/03/2004 yes no yes no  
NS-070 NS ? no None None None   
NS-070 NS ? no None None None   
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
NS-070 NS ? no None None None   
NS-071 NS ? no None None None   
NS-071 NS ? no None None None   
NS-071 NS ? no None None None   
NS-071 NS ? no None None None   
NS-071 NS ? no None None None   
NS-071 NS ? no None None None   
NS-072 NS ? no None None None   
NS-072 NS ? no None None None   
NS-074 NS ? no None None None   
NS-074 NS ? no None None None   
NS-075 NS 15/03/2004 no None None None   
NS-075 NS 19/07/2004 no None None None   
NS-076 NS ? no None None None   
NS-077 NS ? no None None None   
NS-077 NS ? no None None None   
NS-077 NS ? no None None None   
NS-077 NS ? no None None None   
NS-077 NS ? no None None None   
NS-078 NS ? no None None None   
NS-078 NS ? no None None None   
NS-078 NS ? no None None None   
NS-079 NS ? no None None None   
NS-079 NS ? no None None None   
NS-080 NS ? no None None None   
NS-080 NS ? no None None None   
NS-080 NS ? no None None None   
NS-080 NS ? no None None None   
NS-080 NS ? no None None None   
NS-081 NS ? no None None None   
NS-081 NS ? no None None None  
NS-082 NS 22/03/2005 yes None None yes 36 
NS-082 NS 05/04/2005 yes None None yes 36 
NS-082 NS 19/04/2005 yes None None yes 36 
NS-082 NS 28/06/2005 yes None yes yes 30 
NS-082 NS 13/07/2005 yes None yes yes 24 
NS-082 NS 07/09/2005 yes None yes yes 3 
NS-083 NS ? no None None None  
NS-085 NS ? no None None None  
NS-086 NS ? no None None None  
NS-086 NS ? no None None None  
NS-087 NS 25/10/2005 no None None None  
RT-044 ORT 21/09/2004 yes None yes yes 5 
RT-044 ORT 14/12/2004 yes None yes yes 5 
RT-044 ORT 15/03/2005 yes None yes yes 5 
RT-008 ORT 12/04/2001 no None None None  
RT-008 ORT 02/11/2004 yes yes yes yes 10 
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None   
RT-008 ORT ? no no no no   
RT-008 ORT ? no None None None   
RT-008 ORT ? no None None None  
RT-009 ORT 28/07/2000 no None None None  
RT-009 ORT 05/12/2000 yes None None yes 14 
RT-009 ORT 20/09/2001 yes None None yes 8 
RT-009 ORT 13/03/2006 yes no yes yes 4 
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-009 ORT ? no None None None  
RT-010 ORT 28/07/2000 no no no no  
RT-010 ORT 07/05/2001 no no no None  
RT-010 ORT ? no None None None  
RT-010 ORT ? no None None None  
RT-024 ORT 20/09/2000 no no no None  
RT-024 ORT 16/04/2001 no no no None  
RT-024 ORT 11/07/2001 no no no None  
RT-024 ORT 22/01/2003 no None None unknown 12 
RT-024 ORT ? no None None None  
RT-024 ORT ? no None None None  
RT-024 ORT ? no None None None  
RT-024 ORT ? no None None None  
RT-027 ORT 02/03/2004 yes yes yes yes 5 
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I.D. 
Number 
Sub-
Arm visit date IS Cellcept Cyclosporine A  steroids 
steroid 
dose 
RT-027 ORT 20/09/2000 no None None None  
RT-027 ORT 16/04/2001 no None None None  
RT-027 ORT 11/07/2001 no None None None  
RT-027 ORT 04/12/2001 no None None None  
RT-035 ORT 12/04/2001 no None None None  
RT-035 ORT 11/07/2001 no None None None  
RT-035 ORT ? no None None None  
RT-035 ORT ? no None None None  
RT-035 ORT ? no None None None  
RT-035 ORT ? no None None None  
RT-038 ORT ? no None None None  
RT-038 ORT ? no None None None  
RT-038 ORT ? no None None None  
RT-038 ORT ? no None None None  
RT-040 ORT ? no None None None  
RT-040 ORT ? no None None None  
RT-040 ORT ? no None None None  
RT-040 ORT ? no None None None  
RT-040 ORT ? no None None None  
RT-041 ORT ? no None None None  
RT-041 ORT ? no None None None  
RT-041 ORT ? no None None None  
RT-041 ORT ? no None None None  
RT-041 ORT ? no None None None  
RT-041 ORT ? no None None None  
RT-043 ORT ? no None None None  
RT-043 ORT ? no None None None  
RT-043 ORT ? no None None None  
RT-043 ORT ? no None None None  
RT-045 ORT 05/07/2005 yes no yes yes 5 
RT-045 ORT ? no None None None  
RT-045 ORT ? no None None None  
RT-050 ORT 22/03/2005 yes yes yes yes 10 
RT-050 ORT 27/09/2005 yes yes yes yes 10 
RT-050 ORT 18/10/2005 yes yes yes yes 10 
RT-050 ORT 07/03/2006 yes yes yes yes 10 
RT-050 ORT 18/04/2006 yes yes yes yes 10 
RT-051 ORT ? no None None None   
RT-051 ORT ? no None None None   
RT-051 ORT ? no None None None   
RT-051 ORT ? no None None None   
RT-051 ORT ? no None None None   
RT-051 ORT ? no None None None   
RT-051 ORT ? no None None None   
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Legend for appendix IV and V 
I.D. number = identification number given to each individual patient 
Sub-arm= type of condition of patient 
Visit-date= date of patient visit to clinic when blood or urine was taken. 
Cellcept= immunosuppressive drug also known as myfortic and 
mycophenolate. 
Cyclosporine A= anti-rejection drug, calcineurin inhibitor. 
IC= immunocompromise 
NS=nephrotic syndrome 
ORT=orthotopic renal transplant 
IS=immune-suppression 
ALL=acute lymphocytic leukemia. 
OHT= orthotopic heart transplant 
HIV=human immuno-defiency virus 
Steroid dose= milligrams 
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V Table of Patients viral loads  
I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
IC-001 ALL 18/02/2000 0 0 
IC-001 ALL 08/12/2000 0 0 
IC-002 OHT 24/02/2000 0 0 
IC-003 OHT 24/04/2000 0 0 
IC-003 OHT ?   317723.5 0 
IC-004 OHT 14/04/2000 0 0 
IC-005 OHT 20/04/2000 0 0 
IC-005 OHT 06/12/2000 0 0 
IC-006 OHT 20/04/2000 0 0 
IC-006 OHT 21/12/2000 0 0 
IC-006 OHT 21/09/2004 0 0 
IC-006 OHT  ?  0 0 
IC-007 ALL 12/05/2000 0 0 
IC-007 ALL 13/07/2001 0 0 
IC-007 ALL  ?  0 0 
IC-011 HIV 08/08/2000 0 0 
IC-011 HIV 09/02/2001 0 0 
IC-011 HIV  ?  0 0 
IC-012 HIV 08/08/2000 0 0 
IC-013 HIV 08/08/2000 0 0 
IC-013 HIV ?   0 0 
IC-014 HIV 10/08/2000 0 0 
IC-014 HIV 15/03/2001 0 0 
IC-014 HIV 21/08/2001 0 0 
IC-015 HIV 29/08/2000 0 0 
IC-015 HIV 15/03/2001 0 0 
IC-015 HIV 13/07/2001 0 0 
IC-015 HIV        ?  0 0 
IC-016 HIV 29/08/2000 0 0 
IC-016 HIV 21/02/2001 0 0 
IC-017 HIV 30/08/2000 0 0 
IC-018 HIV 30/08/2000 0 0 
IC-018 HIV 21/02/2001 150 0 
IC-018 HIV ?   0 0 
IC-019 HIV 06/09/2000 0 0 
IC-020 ALL 11/09/2000 0 0 
IC-020 ALL 05/03/2001 0 0 
IC-020 ALL ? 0 0 
IC-020 ALL ? 0 0 
IC-021 HIV 19/09/2000 0 0 
IC-021 HIV 13/07/2001 0 0 
IC-022 HIV 19/09/2000 0 0 
IC-022 HIV 13/07/2001 0 0 
IC-022 HIV 06/09/2001 0 0 
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I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
IC-023 HIV 19/09/2000 0 0 
IC-023 HIV 15/03/2001 0 0 
IC-023 HIV 06/09/2001 0 0 
IC-025 OHT 27/09/2000 0 0 
IC-025 OHT 13/12/2000 0 0 
IC-026 HIV ?   150 0 
IC-028 OHT 29/09/2000 0 0 
IC-028 OHT ?   0 0 
IC-030 OHT 09/02/2001 0 0 
IC-031 HIV 16/02/2001 3619250 0 
IC-034 ALL 12/04/2001 0 0 
IC-034 ALL 11/07/2001 0 0 
IC-036 ALL 16/04/2001 0 0 
IC-036 ALL 16/04/2001 0 0 
IC-046 OHT  ?  0 0 
NS-001 NS 06/09/2000 0 0 
NS-002 NS 13/11/2000 0 0 
NS-002 NS 12/04/2001 0 0 
NS-002 NS 18/07/2001 0 0 
NS-002 NS 25/09/2002 0 0 
NS-002 NS 07/04/2004 0 0 
NS-002 NS 28/07/2004 0 0 
NS-002 NS 28/12/2004 0 0 
NS-002 NS 02/01/2005 0 0 
NS-002 NS 19/04/2005 0 0 
NS-002 NS 07/11/2005 0 0 
NS-002 NS 28/02/2006 0 0 
NS-003 NS 13/11/2000 0 0 
NS-003 NS 27/08/2001 0 0 
NS-003 NS 29/08/2001 343898 0 
NS-003 NS 10/09/2001 0 0 
NS-003 NS 25/09/2002 120800 0 
NS-003 NS 10/03/2004 0 0 
NS-003 NS 19/01/2005 7650 0 
NS-004 NS 13/11/2000 0 0 
NS-004 NS 23/04/2001 0 0 
NS-004 NS 21/05/2001 0 0 
NS-004 NS 18/07/2001 0 0 
NS-004 NS 14/08/2001 0 0 
NS-004 NS 24/11/2004 13179750 0 
NS-004 NS 04/01/2005 19763350 1950 
NS-004 NS 09/02/2005 0 0 
NS-004 NS 06/04/2005 0 0 
NS-004 NS 28/06/2005 0 0 
NS-004 NS 20/07/2005 0 0 
NS-004 NS 27/09/2005 0 0 
NS-004 NS 07/11/2005 0 0 
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I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
NS-005 NS 13/11/2000 0 0 
NS-005 NS 07/05/2001 0 0 
NS-005 NS 09/07/2001 0 0 
NS-005 NS 10/09/2001 0 0 
NS-005 NS 14/01/2002 0 0 
NS-005 NS 19/01/2005 1150125000 0 
NS-005 NS 19/04/2005 287573.5 0 
NS-005 NS 28/06/2005 190111.5 0 
NS-005 NS 19/07/2005 500 0 
NS-005 NS 29/11/2005 77000 0 
NS-006 NS 13/11/2000 100 0 
NS-006 NS 14/01/2002 0 0 
NS-006 NS 25/10/2004 0 0 
NS-006 NS 31/01/2005 0 0 
NS-006 NS 22/08/2005 24600 0 
NS-007 NS 02/12/2000 0 0 
NS-007 NS 31/01/2005 0 0 
NS-007 NS ? 0 0 
NS-007 NS ? 0 0 
NS-007 NS ? 0 0 
NS-007 NS ? 0 0 
NS-007 NS ? 0 0 
NS-007 NS ? 0 0 
NS-007 NS ? 0 0 
NS-007 NS ? 0 0 
NS-007 NS ? 0 0 
NS-008 NS 14/11/2000 0 0 
NS-008 NS 27/08/2001 0 0 
NS-008 NS 23/07/2002 0 0 
NS-008 NS 02/12/2002 0 0 
NS-009 NS 16/11/2000 0 0 
NS-009 NS 14/05/2001 0 0 
NS-009 NS 10/09/2002 0 0 
NS-010 NS 04/12/2000 0 0 
NS-010 NS 28/02/2001 0 0 
NS-010 NS 17/09/2001 0 0 
NS-010 NS 04/09/2002 0 0 
NS-011 NS 04/12/2000 0 0 
NS-011 NS 05/03/2001 0 0 
NS-011 NS 14/01/2002 0 0 
NS-011 NS 29/07/2002 67500 0 
NS-011 NS 24/02/2003 0 7150 
NS-011 NS 22/03/2004 0 5250 
NS-011 NS 24/11/2004 0 1250 
NS-011 NS 21/05/2201 0 0 
NS-012 NS 05/12/2000 0 0 
NS-013 NS 05/12/2000 0 0 
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I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
NS-014 NS 01/12/2000 0 0 
NS-015 NS 07/12/2000 0 0 
NS-015 NS 16/10/2002 0 0 
NS-015 NS 24/01/2005 0 0 
NS-016 NS 18/09/2001 0 0 
NS-017 NS 18/12/2000 0 23100 
NS-017 NS 17/09/2001 0 101750 
NS-017 NS 16/01/2002 0 0 
NS-017 NS 31/07/2002 298400 78500 
NS-017 NS 10/01/2005 0 0 
NS-017 NS 11/04/2005 0 0 
NS-017 NS 15/08/2005 400 67850 
NS-018 NS 18/12/2000 0 0 
NS-018 NS 27/08/2001 0 0 
NS-018 NS 06/01/2004 0 0 
NS-018 NS 05/07/2005 0 0 
NS-018 NS 28/02/2006 0 0 
NS-019 NS ? 0 0 
NS-019 NS ? 0 0 
NS-020 NS 19/02/2001 0 0 
NS-020 NS 05/03/2001 0 0 
NS-021 NS 26/02/2001 0 0 
NS-021 NS 22/07/2002 0 0 
NS-022 NS 26/02/2001 0 0 
NS-023 NS 28/02/2001 0 0 
NS-023 NS 23/04/2001 0 0 
NS-023 NS 01/08/2002 187600 0 
NS-023 NS 26/08/2002 2900 0 
NS-023 NS 03/02/2003 0 0 
NS-023 NS 10/11/2004 0 0 
NS-023 NS 12/01/2005 0 0 
NS-023 NS 23/03/2005 0 0 
NS-023 NS 13/07/2005 0 0 
NS-023 NS 26/04/2006 0 0 
NS-024 NS 05/03/2001 0 0 
NS-024 NS 08/10/2001 0 0 
NS-024 NS 12/10/2004 0 0 
NS-024 NS 18/01/2005 0 0 
NS-024 NS 05/07/2005 0 0 
NS-025 NS 21/01/2003 0 0 
NS-025 NS 26/02/2003 0 0 
NS-025 NS 22/03/2004 0 0 
NS-025 NS 20/12/2004 0 0 
NS-025 NS 05/07/2005 0 0 
NS-025 NS ?   0 0 
NS-026 NS 12/03/2001 0 400 
NS-026 NS 23/04/2001 0 1200 
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I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
NS-027 NS 13/03/2001 0 0 
NS-028 NS 27/03/2001 0 0 
NS-028 NS 07/05/2001 0 0 
NS-028 NS 01/10/2002 0 0 
NS-028 NS 10/11/2004 0 0 
NS-028 NS 01/02/2005 0 0 
NS-028 NS 29/03/2005 39150 0 
NS-028 NS 20/09/2005 6000 0 
NS-029 NS 16/04/2001 0 0 
NS-029 NS 07/05/2001 1101350 0 
NS-030 NS 16/04/2001 0 0 
NS-030 NS 10/09/2001 0 0 
NS-030 NS 28/10/2002 0 0 
NS-030 NS 15/11/2004 0 0 
NS-030 NS 06/03/2006 0 0 
NS-031 NS 07/05/2001 0 0 
NS-031 NS 28/08/2002 102750 0 
NS-031 NS 01/03/2004 0 0 
NS-031 NS 24/08/2005 0 0 
NS-032 NS 07/05/2001 0 0 
NS-032 NS 09/07/2001 0 0 
NS-032 NS 30/03/2004 0 0 
NS-032 NS 22/12/2004 0 0 
NS-032 NS 26/01/2005 0 0 
NS-032 NS 29/03/2005 0 0 
NS-032 NS 21/09/2005 0 0 
NS-032 NS 19/10/2005 0 0 
NS-032 NS 15/11/2005 0 0 
NS-032 NS 15/03/2006 0 0 
NS-032 NS 25/04/2006 0 0 
NS-034 NS 14/05/2001 0 0 
NS-034 NS 22/03/2004 0 0 
NS-034 NS 30/03/2004 0 0 
NS-034 NS 29/09/2004 0 0 
NS-035 NS 21/05/2001 0 0 
NS-035 NS 01/10/2002 26200 0 
NS-035 NS 10/12/2002 0 0 
NS-035 NS 14/03/2006 0 0 
NS-036 NS 21/05/2001 0 0 
NS-036 NS 14/01/2002 0 0 
NS-036 NS 19/08/2002 0 0 
NS-036 NS 04/02/2003 0 0 
NS-036 NS 19/07/2004 0 0 
NS-036 NS 05/11/2004 0 0 
NS-036 NS 18/07/2 005 0 0 
NS-037 NS ? 0 0 
NS-037 NS ? 0 0 
Polyomavirus Excretion in Pediatric Renal Disease                                          Julie Moran 
____________________________________________________________________________________________________________ 
________________________________________________________________________ 120
I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
NS-037 NS 07/06/2001 0 0 
NS-037 NS 09/07/2001 0 0 
NS-037 NS 10/09/2001 0 0 
NS-037 NS 22/07/2002 0 0 
NS-037 NS 24/02/2003 0 0 
NS-037 NS 14/12/2004 0 0 
NS-038 NS 06/06/2001 0 0 
NS-038 NS 07/06/2001 0 0 
NS-038 NS 06/07/2001 0 0 
NS-038 NS 17/09/2001 106400 0 
NS-038 NS 10/12/2002 0 0 
NS-038 NS 13/01/2003 0 0 
NS-039 NS 16/07/2001 0 0 
NS-039 NS 10/09/2001 0 0 
NS-039 NS 14/03/2003 0 0 
NS-039 NS 19/03/2004 0 0 
NS-039 NS 01/02/2005 0 0 
NS-039 NS 10/08/2005 0 0 
NS-039 NS 19/09/2005 0 0 
NS-039 NS 10/10/2005 0 0 
NS-040 NS 16/07/2001 0 0 
NS-040 NS 18/07/2001 0 0 
NS-041 NS 13/08/2001 0 0 
NS-041 NS 21/08/2002 5850 0 
NS-042 NS 14/08/2001 0 0 
NS-042 NS 17/09/2001 0 0 
NS-043 NS 14/08/2001 0 0 
NS-043 NS 01/08/2002 25250 0 
NS-043 NS 02/12/2002 0 0 
NS-043 NS 01/12/2004 0 0 
NS-043 NS 14/02/2005 0 0 
NS-043 NS 28/03/2005 0 0 
NS-043 NS 05/07/2005 0 0 
NS-043 NS 19/09/2005 0 0 
NS-043 NS 05/12/2005 0 0 
NS-044 NS 20/08/2001 0 0 
NS-044 NS 26/08/2002 22400 0 
NS-044 NS 28/10/2002 0 0 
NS-044 NS 20/12/2004 0 0 
NS-044 NS 17/10/2005 0 0 
NS-044 NS 07/11/2005 0 0 
NS-045 NS 10/09/2001 0 0 
NS-046 NS 18/09/2001 0 0 
NS-047 NS 18/09/2001 0 0 
NS-047 NS ? 0 2050 
NS-047 NS ? 0 44500 
NS-048 NS 18/09/2001 3539750 0 
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I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
NS-050 NS 08/10/2001 0 0 
NS-051 NS 07/10/2002 0 0 
NS-051 NS ? 0 0 
NS-051 NS ? 0 0 
NS-051 NS ? 0 0 
NS-051 NS ? 0 0 
NS-051 NS ? 0 0 
NS-051 NS  ?   0 0 
NS-052 NS 14/10/2002 0 0 
NS-052 NS ? 0 0 
NS-052 NS ? 0 0 
NS-053 NS 15/10/2002 570350 0 
NS-053 NS 11/02/2005 461850 0 
NS-053 NS 12/04/2005 0 0 
NS-053 NS 29/11/2005 0 0 
NS-054 NS 23/10/2002 0 0 
NS-054 NS ?   0 0 
NS-055 NS 28/10/2002 0 0 
NS-055 NS 24/02/2003 0 290 
NS-055 NS 08/11/2004 0 63.5 
NS-055 NS 24/01/2005 0 13500 
NS-055 NS 12/07/2005 0 0 
NS-055 NS 17/10/2005 0 0 
NS-056 NS 14/01/2003 0 0 
NS-057 NS 14/01/2003 0 0 
NS-058 NS 22/01/2003 0 0 
NS-061 NS ? 0 0 
NS-061 NS ? 0 0 
NS-062 NS ? 0 0 
NS-063 NS 04/02/2003 0 0 
NS-064 NS 11/02/2003 0 0 
NS-064 NS ? 0 0 
NS-064 NS ? 0 48050 
NS-065 NS ? 1644500000 3108243.5 
NS-065 NS ? 0 0 
NS-065 NS ? 0 0 
NS-066 NS ? 0 0 
NS-068 NS 26/02/2003 0 0 
NS-069 NS 02/03/2004 0 0 
NS-069 NS 14/12/2004 0 0 
NS-070 NS 03/03/2004 0 0 
NS-070 NS ? 0 0 
NS-070 NS ? 0 0 
NS-070 NS ? 0 0 
NS-071 NS ? 0 0 
NS-071 NS ? 0 0 
NS-071 NS ? 0 0 
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I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
NS-071 NS ? 0 0 
NS-071 NS ? 0 0 
NS-071 NS ? 0 0 
NS-072 NS ? 137950 0 
NS-072 NS ? 0 0 
NS-074 NS ? 236150 0 
NS-074 NS ? 16750 0 
NS-075 NS 15/03/2004 0 0 
NS-075 NS 19/07/2004 32500 0 
NS-076 NS ? 0 0 
NS-077 NS ? 0 0 
NS-077 NS ? 0 0 
NS-077 NS ? 0 0 
NS-077 NS ? 0 0 
NS-077 NS ? 0 0 
NS-078 NS ? 0 0 
NS-078 NS ? 0 0 
NS-078 NS ? 0 0 
NS-079 NS ? 0 0 
NS-079 NS ? 0 0 
NS-080 NS ? 0 0 
NS-080 NS ? 0 0 
NS-080 NS ? 0 0 
NS-080 NS ? 0 0 
NS-080 NS ? 0 0 
NS-081 NS ? 0 0 
NS-081 NS ? 0 0 
NS-082 NS 22/03/2005 0 0 
NS-082 NS 05/04/2005 0 0 
NS-082 NS 19/04/2005 0 0 
NS-082 NS 28/06/2005 0 0 
NS-082 NS 13/07/2005 0 0 
NS-082 NS 07/09/2005 0 0 
NS-083 NS ? 0 330400 
NS-085 NS ? 0 0 
NS-086 NS ? 0 0 
NS-086 NS ? 0 0 
NS-087 NS 25/10/2005 0 0 
R-044 ORT 21/09/2004 19702.5 0 
R-044 ORT 14/12/2004 76100 0 
R-044 ORT 15/03/2005 0 0 
RT-008 ORT 12/04/2001 0 0 
RT-008 ORT 02/11/2004 0 0 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 0 
Polyomavirus Excretion in Pediatric Renal Disease                                          Julie Moran 
____________________________________________________________________________________________________________ 
________________________________________________________________________ 123
I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 0 
RT-008 ORT ? 0 3900 
RT-008 ORT ? 0 92550 
RT-009 ORT 28/07/2000 0 0 
RT-009 ORT 05/12/2000 0 0 
RT-009 ORT 20/09/2001 0 0 
RT-009 ORT 13/03/2006 0 0 
RT-009 ORT ? 1239715 0 
RT-009 ORT ? 27500 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-009 ORT ? 0 0 
RT-010 ORT 28/07/2000 0 0 
RT-010 ORT 07/05/2001 0 0 
RT-010 ORT ? 0 0 
RT-010 ORT ? 0 147750 
RT-024 ORT 20/09/2000 0 0 
RT-024 ORT 16/04/2001 0 0 
RT-024 ORT 11/07/2001 0 0 
RT-024 ORT 22/01/2003 0 0 
RT-024 ORT ? 15250000000 0 
RT-024 ORT ? 9000000000 0 
RT-024 ORT ? 1329950 0 
RT-024 ORT ? 188400 0 
RT-027 ORT 02/03/2004 20788.5 0 
RT-027 ORT 20/09/2000 0 0 
RT-027 ORT 16/04/2001 0 0 
RT-027 ORT 11/07/2001 0 0 
RT-027 ORT 04/12/2001 0 0 
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I.D. 
Number 
Sub-
Arm visit date 
Real-time BKV 
copies/ml 
Real-time JCV 
copies/ml 
RT-035 ORT 12/04/2001 0 0 
RT-035 ORT 11/07/2001 0 0 
RT-035 ORT ? 234402.5 0 
RT-035 ORT ? 0 0 
RT-035 ORT ? 0 0 
RT-035 ORT ? 0 0 
RT-038 ORT ? 0 0 
RT-038 ORT ? 0 0 
RT-038 ORT ? 0 0 
RT-038 ORT ? 0 0 
RT-040 ORT ? 0 0 
RT-040 ORT ? 0 800 
RT-040 ORT ? 0 35159.5 
RT-040 ORT ? 0 1449.5 
RT-040 ORT ? 0 247000 
RT-041 ORT ? 0 0 
RT-041 ORT ? 0 0 
RT-041 ORT ? 0 0 
RT-041 ORT ? 0 0 
RT-041 ORT ? 0 100 
RT-041 ORT ? 0 1100 
RT-043 ORT ? 703400 650 
RT-043 ORT ? 240200 384750 
RT-043 ORT ? 148650 0 
RT-043 ORT  ? 100280 7550 
RT-045 ORT 05/07/2005 0 0 
RT-045 ORT ? 1300 0 
RT-045 ORT ? 0 0 
RT-050 ORT 22/03/2005 0 0 
RT-050 ORT 27/09/2005 0 0 
RT-050 ORT 18/10/2005 0 0 
RT-050 ORT 07/03/2006 0 0 
RT-050 ORT 18/04/2006 0 0 
RT-051 ORT ? 0 0 
RT-051 ORT ? 0 0 
RT-051 ORT ? 0 0 
RT-051 ORT ? 0 0 
RT-051 ORT ? 0 0 
RT-051 ORT ? 0 0 
RT-051 ORT ? 0 0 
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VI     VP1  Sequences. 
 
VP_11 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGGTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTCAAAATGACTTTAGCAGTGATAGCCCAGAA
AGAAAAATGCTTCCTTGTTACAGCACAGCAAGAATTCCCCTCCCCAATTTAAATGAGGA 
VP_12 
GTGCCAAAAATACTAATAAAAGGAGGAGTAGAAGTTTTAGAAGTTAAAACTGGGCTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCCGAA
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTCCCCAGTTTAAATGAGGT 
VP_13 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGCTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAC
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTCCCCAATTAAAAGTGGAT 
VP_23 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGGTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACT
CTAGGGGCTTTAGTCTAAAGTTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAA
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTCCCCAATTTCAAGTGGAT 
VP_24 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGGTAGA
TGCTATTACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAG
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTGCCCAATTTAAATGAGGA 
VP_25 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGCTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAC
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTCCCCAATTTAAATGAGGT 
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VP_26 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGCTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
CTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAC
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTCCCCAATTTTAATGAGGT 
VP_27 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGCTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAC
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTCCCCAATTTAAATGAGGA 
VP_28 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGGTAGA
TGCTATTACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAG
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTGCCCAATTTAAATGAGGA 
VP_29 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGCTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAC
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTCCCCAATTTAAATGAGGA 
VP_39 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGGTAGA
TGCTATTACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
CTAGGGGCTTTAGTCTAAAGTTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAG
AGAAAAATGCTTCCCTGTTACAGCACCGCAAGAATTCCCCTGCCCAATTTCATGTCGAT 
VP_40 
GTGCCAAAACTACTAATAAAAGGAGGAGTAGAAGTTCTAGAAGTTAAAACTGGGGTAGA
TGCTATAACAGAGGTAGAATGCTTCCTAAACCCAGAAATGGGGGATCCAGATGAAAACC
TTAGGGGCTTTAGTCTAAAGCTAAGTGCTGAAAATGACTTTAGCAGTGATAGCCCAGAA
AGAAAAATGCTTCCCTGTTACAGCACAGCAAGAATTCCCCTCCCCAATTTAAATGAGGA 
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